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Weihsu Claire Chen, PhD 
University of Pittsburgh, 2007
 
 
Human papillomavirus (HPV) oncoproteins E6 and E7 which are constitutively expressed in 
cervical cancer cells are ideal targets for developing immunotherapies for treatment of existing 
HPV-associated carcinoma. In this project, we developed a simple, safe, and efficient, peptide-
based therapeutic cancer vaccine, DOTAP/E7 complex, which comprises only two molecules: a 
DOTAP cationic lipid and an MHC class I-restricted peptide antigen derived from HPV-16 E7 
protein. TC-1 cell line which is HPV-16 E7+ was used as a tumor model in an H-2b murine 
system. Tumor-bearing mice showed significant tumor inhibition following a single injection of 
DOTAP/E7 at the optimal lipid dose, suggesting that DOTAP liposome alone can be a potent 
adjuvant. E7 peptide formulated with DOTAP was taken up by dendritic cells (DC) and induced 
DC activation and migration to the draining lymph node (DLN), eliciting antigen-specific CD8+ 
cytotoxic T lymphocyte (CTL) responses. The mechanism of DOTAP as a vaccine adjuvant was 
revealed by DOTAP-mediated reactive oxygen species (ROS) production in DC. At the optimal 
lipid dose, DOTAP/E7 generates an adequate level of ROS for the initiation of the vaccine 
mechanism. In addition, we have improved the vaccine formulation by incorporation of E7-
lipopeptide instead of the water-soluble native E7 peptide. The improved DOTAP/E7-
lipopeptide vaccine showed a significantly enhanced therapeutic effect, including CTL response 
and anti-tumor activity. The vaccine was also effective for suppression of tumor growth in later 
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stages of tumor progression, suggesting applications for advanced cancer treatment. Furthermore, 
we extended the studies of the vaccine efficacy observed in the mouse model to human cells in 
vitro. Instead of H-2Db-restricted peptide, an HLA-A2-restricted E7 peptide epitope (hE7) was 
formulated into the liposome. In vitro stimulation of naïve HLA-A2+ human T lymphocytes by 
DOTAP/hE7-activated autologous DC elicited a stronger clonal T cell proliferation and higher 
HPV-specific CTL response compared to those stimulated with DC pulsed with hE7 peptide 
alone. The in vivo CTL and anti-tumor activity induced by DOTAP/hE7 vaccine were 
demonstrated in an HLA-A2 transgenic mouse model. Overall, our data suggest that 
DOTAP/hE7 is a potent therapeutic cancer vaccine formulation with potential for clinical 
applications for the treatment of HPV-related neoplasia. 
 v 
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1.0  INTRODUCTION 
1.1 INDUCTION OF IMMUNE RESPONSES AGAINST CANCER 
1.1.1 Tumor immunology: from immune surveillance to immune escape 
Immune surveillance was first identified in the early 20th century by Ehrlich et al. as a 
phenomenon that recognizes the transformed cells and destroys them before they are clinically 
detected. A virus-infected cell or tumor cells can be caught and eliminated by NK cells in the 
innate immune system [1]. However, tumor cells display multiple mechanisms to avoid the 
recognition by the innate and adoptive immune responses [2]. Indeed, several therapeutic vaccine 
studies have failed to inhibit the tumor growth in vivo even if they were capable of generating 
tumor associated antigen (TAA) specific cytotoxicity. In order to develop a suitable 
immunotherapy for treatment of cancer, it is important to understand the strategies that tumor 
cells use to escape from the immune surveillance. A current concept of the tumor immunoediting 
which leads to immune escape was proposed. It consists of elimination, equilibrium and escape 
[3].  
During the elimination stage, the nascent tumors are detected by innate immune response 
and some of the transformed cells are killed by IFN-γ secreted by NK/NKT cells [4]. Adaptive 
immunity is initiated by ingestion of dead tumor cells by dendritic cells (DC). Migration of 
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mature DC to the draining lymph node followed by antigen presentation to naïve CD4+ or CD8+ 
cells essentially generates tumor cell antigen-specific T lymphocytes [5]. If any tumor cell 
variants have survived the elimination process, those cells continue to grow under an equilibrium 
status in the presence of IFN-γ and other immune cells [6]. Under this condition, the new tumor 
variants (usually the mutant) become less immunogenic and resistant to immune attack. The 
phase of equilibrium could be the longest among the three stages [7]. Eventually, tumor cells 
escape from immune surveillance and expand in an immunologically intact condition. In order to 
keep tumor progression, tumor cells also adopt some immunosuppressive strategies as follows: 
Impairment of TCR signaling: Tumor cells-induced CD3ζ chain decrease in tumor 
infiltrating T cells (effectors), impairs the recognition of antigen and TCR-CD3 complex. Several 
clinical studies confirmed defects from CTL in patients with different cancer types [8] [9]. 
Secretion of immunosuppressive factors: A variety of tumor-derived soluble proteins 
such as VEGF, TGF-β, IL-10 have been extensively studied in the recent decade [10] [11] [12]. 
These immunosuppressive cytokines are produced in the tumor microenvironment and inhibit T 
cell activation and proliferation. 
Activation of negative regulatory factors: Tumor cells produce FasL or an 
immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO) which promotes apoptosis in 
effector cells [13]. In addition, cancer cells also induce the activation of CTLA-4 and 
programmed death 1 (PD-1) in T cells. These molecules bind to B7 molecules to block the 
costimulatory signaling [14] [15].  
Regulatory T cells (Treg): Significant interest has recently focused on 
CD4+CD25+Foxp3+ Treg. Many Treg populations can be found in the lung, breast, ovary and 
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skin cancer patients [16]. Increased Treg population in tumor and malignant ascites inversely 
correlates with the low survival rate of cancer patient. 
1.1.2 Dendritic cells activation and toll-like receptors 
Dendritic cells (DC) are considered the most effective antigen-presenting cells (APC) for 
generating immune responses. Since presentation of antigens to the immune system by 
appropriate professional APC is essential to elicit a strong immune reaction, DC holds great 
promise to improve the efficacy of cancer vaccines. At least six subsets of DC have been 
described in mouse including myeloid DC (mDC), plasmacytoid DC (pDC) and Langerhans cells 
which are also found in human [17]. mDC are potent APC and are associated with T cell 
activation, while pDC are considered to be specialized to secret type I interferon after stimulation 
with a virus. Both lymphoid and myeloid progenitors in bone marrow are able to differentiate 
into pDC and mDC [18]. Antigens can be taken up by DC in the peripheral tissue via recognition 
of DC surface receptors such as scavenger receptor or toll-like receptors (TLR). And the signals 
mediated through TLR enable DC maturation and migration to the lymph node. 
TLRs were identified as the major recognition receptor for pathogen associated molecule 
pattern (PAMP) such as LPS, peptidoglycan, lipoteichoic acid and CpG-containing 
oligonucleotides (CpG ODN) [19] [20] [21]. Accumulated evidence has demonstrated that TLRs 
are the critical link between the innate and the adaptive immunities. TLRs are membrane 
proteins containing leucine-rich repeats (LRR) and an intracellular IL-1R-like domain [22] [23]. 
More than twelve TLRs have been identified and different TLRs can exert distinct but 
overlapping sets of biological effects [24]. All of these molecules are involved in engaging and 
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controlling the innate immune response, which is essential for pathogen elimination, and in 
orchestrating the transition to an adaptive immune response [25]. 
The link between adjuvants and TLRs in triggering adaptive immunity as well as 
subsequent signaling pathways has been a subject of many recent investigations. An adjuvant 
alerts the host immune system through a mechanism similar to that of an infection by a pathogen, 
which may involve interaction with a TLR followed by a danger signal to the immune system. 
For example, the unmethylated bacterial CpG-DNA, recognized by TLR9, was used as an 
adjuvant for cancer therapy to induce a helper T cell 1 (Th1)-type T-cell response. TLR9-
deficient mice did not show any responses to CpG-DNA, including Th1 cytokine production, B-
cell proliferation, and maturation of DCs [19]. Subsequent signal transduction activated by TLRs 
involves two major pathways [26]. The first pathway includes the activation of transcription 
factor NF-κB, which acts as a master switch for inflammation, regulating the transcription of 
many genes that encode proteins involved in immunity and inflammation. The second pathway 
triggers the activation of p38 and Jun amino-terminal (JNK) MAP kinases. Although NF-κB and 
MAP kinases can be activated by all TLRs, there are differences in the ultimate gene expression 
profile induced by individual TLRs 
1.1.3 Activation of cytotoxic T lymphocytes 
Induction of cytotoxic T lymphocyte (CTL) response is essential for eliminating virus-infected 
cells and tumor cells. During adaptive immune responses, CTL activation requires at least two 
signals: antigen recognition and costimulatory interaction. Mature DC migrate to the secondary 
lymphoid tissue such as spleens, LN where they stimulate naïve T cells by presentation of 
antigen-major histocompatibility (MHC) complex (signal 1). Antigen presentation alone can 
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activate pathogen-specific T-cells, but is not sufficient to trigger efficient T-cell expansion. 
Clonal T-cell expansion requires an additional signal delivered by costimulatory molecules such 
as CD80 and CD86. Signal 2 involves the interaction between costimulatory molecules on DC 
and CD28 on T cells. In absence of signal 2, T cells recognizing the antigen presented by DC are 
tolerized [27]. Many recent studies have shown that CD4+ helper T cells are required for 
efficiently priming of memory CD8+ CTLs. The cross-talk between CD4+ T cells and DC 
essentially results in IL-12 production by DC, leading to a Th1 immune response. 
1.1.4 Chemokines  
The chemokines are a superfamily of small secretory peptides which were originally identified as 
potent chemoattractants for inflammatory cells including neutrophils, eosinophils, and 
monocytes/macrophages [28]. Subsequent studies have revealed that chemokines, especially 
CCR7 and its ligands (CCL19 and CCL21) have profound effects on immune reactions by 
regulating the trafficking of DC as well as other lymphocytes into the secondary lymphoid 
organs [29]. Since lymphatic endothelial cells are known to constitutively produce CCL21, The 
migration of mature DC from peripheral tissue to DLN and the antigen presentation to T cells are 
reflected by CCR7 expression [30]. Eventually, a small population of central memory T cells 
(CCR7+CD62L+) will lose their LN-homing receptors and become effector memory T cells 
(CCR7-CD62L+). The effector memory T cells leave LN and play important roles in eliminating 
tumor cells with distinctive antigens. 
MCP-1/CCL2, a member of CC chemokines, was originally identified as chemotactic and 
activating factor for monocytes/macrophages [31]. Subsequent studies showed that it can also 
affect the function of T-cells, natural killer cells and neutrophils [32]. Further studies found that 
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MCP-1/CCL2 was the most potent activator of CD8+ CTL activity [33], in the presence of Th1 
cytokines, IL-12 and IFN-γ. Recently, it has been shown that chemokines enhance immunity by 
guiding naïve CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction and promote 
memory CD8+ T-cell generation [34] [35].  
1.2 DEVELOPMENT OF THE CERVICAL CANCER VACCINE 
1.2.1 Human papillomavirus and cervical cancer 
Cancer of the uterine cervix is the second most common cancer among women worldwide. The 
incidence rate is about 10 per 100,000 in developed countries and 40 per 100,000 in developing 
countries, with approximately 500,000 new cases being diagnosed each year [36]. Among these 
patients, 45% of them die usually as a result of distant metastases. It is widely accepted that the 
human papillomaviruses (HPV) are the cause of nearly all cervical cancers and over 99.7% of 
cervical cancers contain HPV DNA, typically of the HPV subtypes 16, 18 and 31. In addition to 
cancers, HPV infection can also cause genital warts [37] and recurrent respiratory papillomatosis 
(RRP) [38]. More than 100 HPV subtypes have been characterized and the most common type of 
HPV associated with cervical cancer is type 16, which causes more than 50% of all cases [39]. 
Over the past 20 years the link between cervical cancer and HPV has been extensively studied. 
HPV belongs to the family papovaviridae and contains a circular double stranded DNA 
genome. Upon infection, HPV randomly integrates into the genome of host cells and induce 
malignant transformation. The HPV genome can be separated into three distinct regions: the 
early (E) genes, late (L) genes and the non-coding upstream regulatory region (URR) [40]. 
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Proteins encoded in the E region of the viral genome such as the E6 and E7, are important for 
inducing and maintaining the transformed phenotype [41] [42]. L region encodes genes for 
capsid proteins. One of the most studied mechanisms of the E6 and E7 oncoproteins is their 
abilities to alternate the functions of tumor-suppressor genes, p53 and retinoblastoma (RB). The 
p53 recognizes the damaged DNA and arrests the cell cycle at G1 phase for DNA repairing. If 
the repair does not occur, p53 induces the apoptosis of the damaged cells. In cervical cancer cells, 
E6 oncoprotein silences the function of p53 by degradation through ubiquitin system [43]. 
Similarly, RB also regulates the cell cycle and E7 oncoprotein inactivate its function by binding 
to phosphorylated RB [44]. As a result of p53 silencing and RB blocking, HPV infected cell are 
allowed to grow unregulated. 
Treatment options for cervical neoplasia depend on the stage of the disease. The non-
invasive cervical intraepithelial neoplasia (CIN) is treated with cryotherapy or laser therapy that 
destroys and removes the abnormal tissue. For early invasive or advanced cancers, 
internal/external radiation therapy and chemotherapy are given to the patients [45]. 
1.2.2 Preventative vaccine against HPV viral infection 
Since HPV is the etiological agent of cervical neoplasia, preventing infection with the 
virus will also prevent development of cervical cancer. Merck’s HPV vaccine, GARDASIL™, 
which is a preventive vaccine against HPV infection, is already available in the market. This 
exciting development for an HPV preventive vaccine is based on immunization of individuals 
with HPV virus-like particles (VLP) in order to generate virus-neutralizing antibodies against 4 
types of HPV (HPV 6, 11, 16, 18) [46]. VLP can be obtained by overexpression of the major 
capsid protein L1 alone, or by co-expression with the minor capsid protein L2 [47] [48]. HPV 
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VLP mimic infectious virions in structure and morphology [49] [50] and in their ability to induce 
high tittered neutralizing antisera, even in the absence of adjuvants [51]. Although VLP vaccine 
has been proven to be safe and effective for HPV infection, it cannot treat patients with 
established cervical neoplasia. Since capsid proteins are not detectably expressed in the basal 
epithelial cells that give rise to benign and malignant lesions, antibodies induced by VLP are 
unlikely to be active in treating established cervical cancer. There are a few studies that show 
vaccination with VLP generating capsid-protein specific cellular immune responses, however, 
such responses alone cannot result in regression of premalignant and malignant lesions in 
humans, but may aid in the prevention of such lesions [52] [53] [54]. 
1.2.3 Therapeutic vaccines against the existing cervical carcinoma 
In order to cure patients who are currently HPV-infected, it is essential to develop a therapeutic 
vaccine for treatment of the HPV-associated lesions. Instead of L1 protein, HPV E6 and E7 
oncoproteins are persistently expressed in the HPV infected cells including tumor cells. E6 and 
E7 proteins are typically intracellular nuclear antigens, but they also encode peptides that can 
serve as tumor rejection antigens [55]. The fact that these are foreign proteins and are not 
presented on the surface of the virus particle, makes them exquisitely tumor specific, and several 
of these antigens induce MHC class I-restricted CTLs. Indeed, active immunization against 
E6/E7 results in protection from tumor challenge [56]. Whereas tumors are dependent on the 
expression of E6 and E7, it provides a strong rational for targeting these proteins as a potential 
therapy for cervical cancer.  
Therapeutic vaccines for treating cervical cancer should stimulate the immune system to 
recognize and directly target HPV viral proteins expressed in the infected cells, thereby 
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preventing the development of lesions and eliminating existing lesions [57] [58]. The choice of 
target antigen is a critical step for developing a potent therapeutic vaccine. Most therapeutic 
approaches have concentrated on eliciting cytotoxic T lymphocytes (CTL) responses against the 
constitutively expressed viral oncogenic antigens of the most prevalent high-risk HPV 16 and 18 
viruses. Since endogenously derived viral peptides of E6 and E7 can traffic through the 
endoplasmic reticulum and Golgi apparatus and be presented on the surface of the infected cells, 
they are potential targets of recognition by CD8+ CTL. In addition, E7 sequence is more 
conserved than that of other peptides and is expressed throughout the life cycle [59]. A number 
of animal studies listed below have indicated that therapeutic HPV vaccines targeting E6/E7 are 
effective in alleviating disease progression [60]. 
Peptide-based vaccines: A large set of both murine and human HPV-16 and HPV-18 
CTL and helper T cell epitopes have been identified [61] [62]. Vaccination with E6/E7 peptide 
or lipidated peptides was found to generate CTL responses in both animals and human [63]. 
Protein-based vaccine: Whereas peptides exhibit MHC restriction, protein-based 
vaccines are independent on patient’s HLA haplotype, thereby including all potentially 
immunogenicity of the targeted protein. Purified viral proteins induce both cellular and humoral 
immune responses including antibody and CD4+ helper T cell responses. Due to the fast 
degradation of injected proteins, the use of adjuvants and multiple immunizations is generally 
required for a potent immune response [64]. 
Life vector-based vaccines: Live viral expression vectors such as vaccinia virus and 
adenovirus have also been used to generate HPV vaccines. The advantage of these vaccines is 
that HPV proteins are endogenously synthesized from the viral DNA by host cells, with the 
result that an array of HPV peptides is produced, processed and presented on the cell surface in 
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conjunction with the MHC class I molecule. Recombinant vaccinia expressing modified E6 and 
E7 antigens of HPV 16 and HPV 18 has been used successfully to provide protection against 
tumor growth in various systems [65] [66]. Adenovirus vectors have the advantage over vaccinia 
vectors of not inducing unwanted side effects associated with replication in mammalian cells and 
being engineered such that they are replication-deficient [67]. Attenuated bacteria such as 
Listeria and Salmonella can also serve as a carrier to deliver engineered plasmids encoding 
proteins of interest. Recent studies have shown that oral vaccination of Listeria monocytogenes 
that express HPV 16 E7 can lead to tumor regression in a mouse model.  
DNA-based vaccines: DNA vaccines which allow for sustained expression of antigen is 
another type of vaccination strategy currently being explored for immunotherapy [68]. 
Immunization with naked DNA in conjunction with various strategies has been tested in various 
HPV16 tumor models [69] [70] [71].  
Chimeric VLP vaccines: Chimeric HPV VLP that incorporate non-structural virus 
proteins such as E6 and E7 or peptide epitopes derived from such proteins offer an exciting 
approach for a combined prophylactic and therapeutic vaccine against HPV-induced lesions [72]. 
Dendritic cell-based vaccines: Bone marrow-derived DC pulsed with HPV 16/18 E7 
peptide or tumor lysate were shown to serve as an effective vaccine, protecting mice against 
challenge with E7-expressing tumor cells and also causing regression of small existing tumors 
[73] [74].  
1.2.4 Therapeutic vaccine in clinical trials 
Several vaccines with safety, immunogenicity and clinical efficacy are currently being developed 
for clinical trials. Although there are no therapeutic vaccines against HPV available in the market 
10 
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so far, several vaccines showed encouraging therapeutic results in the clinical trials (summarized 
in Table 1.1). A head-to-head comparison of these trials will help the design of a potent 
therapeutic vaccine with minimal toxicity [75]. The clinical trials also provide a good 
opportunity to investigate the mechanism of the immune response mediated by vaccine. This will 
greatly facilitate the rational design and development of improved therapeutic vaccines.  
Most of the vaccines in the clinical trial utilized vaccine adjuvant or/and particulate 
delivery systems to enhance the immunological response. In a phase I clinical trial, 18 women 
with high grade HPV 16+ CIN were given an HLA-A2-resticted peptide (E712-20) in incomplete 
Freund’s adjuvant. DC infiltrate was observed in 6 of 6 patients while CTL response was 
observed in 10 of 16 patients. Also, 3 out of 17 patients cleared their dysplasia after vaccination 
[76]. In a more recent clinic trial, Sheets et al. utilized pDNA encoding a 13 a.a. sequence 
(homologous with HPV E7) delivered by a poly lactide-co-glycolide microparticle (ZYC101) for 
a Phase I trial [77]. The results showed a 33% complete histologic responses, a 73% 
immunologic response, and no serious adverse events after treatment by ZYC101. These studies 
have demonstrated clearly the relevant biological and clinic effects of the HPV therapeutic 
peptide vaccines and, therefore, the potential for the management of the cervical cancer. 
 
12 
 
Table 1.1. Clinical trials for therapeutic vaccines against cervical cancer 
Antigen used Delivery system Study group Outcome Reference 
pDNA (HPV 16 E7 
peptide sequence) 
Microparticles 
(ZYC101) 
Phase I E2 specific immunity [77] 
HPV 16/18 E6/E7 gene Recombinant 
vaccinia virus 
Late stage cervical cancer Mild increase in antibody titer 
and CTL response 
[78] 
HPV 16 E711-20 peptide  Emulsion with 
Freund’s adjuvant 
Phase II/III: high-grade cervical 
or vulvar intraepithelial 
neoplasia 
10/16 had positive response 
and 12/18 cleared the virus 
[76] 
pDNA (HPV 16 E7) Microparticles 
(ZYC101a) 
High-degree anal intraepithelial 
lesions and high-grade CIN 
33% had complete response 
and 73% showed 
immunological response 
[79] 
pDNA (attenuated HPV 16 
E7 fused to Hsp70)  
- HPV 16 positive head and neck 
cancer 
Ongoing [59] 
E786-93 lipopeptide - Phase I: refractory cervical 
cancer or vaginal cancer  
Positive CTL response but no 
clinical responses 
[63] 
Two HPV 16 E7 peptides 
plus one helper peptide 
Emulsion with 
Montanide ISA51 
adjuvant 
Phase I/II: recurrent cervical 
cancer 
2/19 showed stable disease and 
2/19 had tumor regression after 
chemotherapy 
[80] 
HPV 18 E7-pulsed 
dendritic cells 
- Patients with metastatic cervical 
cancer 
Induction of tumor-specific 
cytotoxicity in tumor 
infiltrating lymphocytes 
[81] 
 
 
1.3 CATIONIC LIPOSOME AS AN ANTIGEN CARRIER AND A CANCER 
VACCINE ADJUVANT 
1.3.1 Peptide cancer vaccine and delivery system 
Synthetic peptide-based vaccines designed to elicit T cell immunity are an attractive approach 
for the prevention and treatment of cancers. Tumor cells express antigens that can be recognized 
by the host immune system. These tumor-associated antigens (TAA), usually small peptides of 
8-10 amino acids, can be injected into patient to induce immune responses that may result in the 
destruction of the cancer [82] [83]. Cytotoxic T lymphocytes recognize TAA that associate with 
MHC class I molecules expressed on the surface of the APC. As a result of the specific 
interaction between the TCR on the CTL and the peptide/MHC complex on the APC, the CTL 
are able to kill tumor cells expressing the TAA [84]. Over the last decade, numerous TAA 
recognized by tumor-reactive CTL have been identified by various molecular and biochemical 
methods [85]. However, most of them showed only limited clinical use for the majority of 
cancers. There are still many obstacles to overcome to take full advantage of the peptide cancer 
vaccines.  
Firstly, the peptide antigen must make its way into the organized lymph tissue such as the 
draining lymph nodes (DLN) or the spleen [86]. This could be accomplished either through 
effective delivery of peptide directly to the lymphoid organs, or by effective targeting of peptide 
to antigen presenting cells (APCs) in the periphery, with concomitant delivery of appropriate 
"danger signals” (such as CpG motif) to induce APC maturation and migration. It has been 
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shown that large amounts of immunogenic antigens are ignored by the immune system, as long 
as they remain outside of the lymphatic system [87].  
Secondly, to induce an effective cellular immunity, antigenic peptides in the lymphoid 
tissues must be presented to T-cells in association with MHC molecules on the surface of the 
APC such as DC. DC are the initiators and modulators of the immune response and as such can 
serve as an attractive target for vaccination strategies. Extracellular peptide antigens are 
generally vulnerable to protease due to the degradation of the minimal epitope. Even if they are 
internalization by the APC, it generally results in delivery to the lysosomal compartment, where 
the minimal epitope is rapidly degraded [88].  
To circumvent these obstacles, a great number of systems have been designed to deliver 
antigenic peptides to the cytoplasm of the APC, from which they could access the MHC class I 
restricted processing pathway. The use of peptides associated with adjuvants or heat shock 
proteins, encapsulated in neutral liposomes or biodegradable polymers, or coupled to synthetic 
beads have all been investigated [89] [90]. Recently, Wang et al demonstrated that ex vivo 
loading of antigen into the cytoplasm of dendritic cells extends the time that it is presented on 
MHC class I molecules and enhances CTL responses [91]. 
1.3.2 LPD mediated peptide vaccination 
Previous work in our lab has led to the development of a novel liposome-based delivery system, 
called LPD [92]. The LPD, originally designed as a DNA delivery system, is self-assembled 
from cationic lipid, protamine and plasmid DNA. LPD is also a novel adjuvant for stimulating 
both humoral and cellular immune responses. Intravenous administration of LPD was found to 
potentiate efficient anti-tumor activity in murine tumor model 24JK cells, even when the 
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formulation contained an empty, non-coding plasmid [93]. The observed anti-tumor activity was 
thought to originate from the innate immunostimulatory activity of the unmethylated CpG motif 
sequences present in the plasmid DNA. It was further correlated with its ability to induce Th-1 
cytokines like TNF-α, IFN-γ and IL-12 and to the development of tumor-specific CD8+ cytotoxic 
lymphocytes (CTL) [94].  
Due to the feature of immunogenicity, LPD particles were used to entrap and deliver 
antigenic peptides to the cytoplasm of APC, thereby enhancing the immune response to peptide 
vaccines. When LPD loaded with a MHC class I-restricted peptide (RAHYNIVTF) epitope 
derived from E7 protein of HPV-16 was used to immunize the mice, a strong antigen-specific 
anti-tumor response was observed [95]. It induced an E7-specific CTL response and prevented 
the establishment of E7-expressing TC-1 tumors, a murine model for human cervical cancer. 
Moreover, administration of LPD/E7 to TC-1 tumor-bearing mice caused complete tumor 
regression. Flow cytometry analysis with fluorescently labeled complexes revealed that LPD/E7 
particles are selectively accumulated in the spleen or the local nymph nodes and are effectively 
taken up by the antigen presenting cells of the immune system. Furthermore, a murine dendritic 
cell line (DC2.4) pulsed with LPD/E7 complex could effectively induce an E7-specific CTL 
response and immunize the mouse against tumor challenge [96]. These data indicated that LPD 
is an excellent carrier for peptide antigen for inducing CTL response against HPV+ tumor. 
1.3.3 Vaccine adjuvant activity of cationic liposome 
To elucidate the immunostimulatory mechanism of LPD and to further improvise its adjuvant 
activity, we investigated a series of detailed mechanistic studies of the stimulatory activity of 
LPD on DC2.4 and bone marrow derived dendritic cells (BMDC). We observed that the cationic 
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lipid part of the LPD formulation significantly influences its immunostimulatory activity on DC. 
Our data show DC activation correlates with the concentration of cationic lipid [97]. The fact 
that cationic lipids alone could stimulate the antigen presenting cells was of high importance 
since the immunomodulatory adjuvant activities of LPD were initially thought to be arising only 
by unmethylated CpG motifs of the plasmid DNA via toll-like receptor 9 (TLR9). Recent studies 
have shown that bacterial CpG motifs may cause acute inflammatory response in humans, thus, it 
is essential to develop a safer vaccine formulation for human use which contains no bacterial 
DNA. 
The immunologic adjuvant property of liposomes was first studied by Allison and 
Gregoriadis [98]. Their results showed that diphtheria toxoid entrapped in liposomes generated a 
strong humoral immune response in mice. Uemura et al. [99] found that liposomes prepared from 
various phospholipids had differential adjuvant activity. The lipid structure determines the 
properties of liposomes including the membrane stability, surface charge, and to some extent, the 
interior properties of the liposome. Therefore, we have systematically investigated structure-
specific immunomodulatory effect of cationic lipids on DC [97]. Our data show some of the 
cationic lipids alone can activate dendritic cells toward expression of surface marker, CD80 and 
CD86, but not the release of TNF-α from DC. DC stimulation was specific to cationic lipids, the 
zwitterionic and anionic lipids showed little or no activity. In general, the cationic lipids bearing 
ethyl phosphocholine head groups were better stimulants than their trimethylammonium 
counterparts. These results suggest the existence of an NF-κB independent immunostimulation 
pathway for cationic lipids such as DOTAP. 
More recently, we found that cationic liposomes, such as DOTAP, can stimulate DC, 
resulting in MAP kinase ERK activation and several chemokine inductions, such as CCL-2 [100]. 
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A proposed signaling pathway of DOTAP is summarized in Fig. 1.1, which reveals a molecular 
mechanism of DOTAP as a vaccine adjuvant. PI-3 kinase is required for DOTAP-induced CCL2 
production and ERK phosphorylation. pERK and CCL2 production in DC are partially inhibited 
when PI-3 inhibitor (i.e. wortmannin) is added. In addition, ERK activation and CCL2 release by 
DOTAP is negatively regulated by p38 pathway. Interestingly, the anti-tumor activity of 
DOTAP/E7 vaccine is significantly decreased when either U-0126 (ERK inhibitor) or SB203580 
(p38 inhibitor) is co-formulated with the vaccine. The result implies that both ERK and p38 
pathway are required by DOTAP-mediated vaccine adjuvant activity [100]. Although the detail 
mechanism is not fully elucidated, our data suggest that DOTAP adjuvant-induced DC activation 
is different from other type of adjuvants which activate DC through TLR signaling, leading to 
NF-κB production. 
 
Figure 1.1. (adopted from Yan, 2007) Proposed signaling pathways leading to DC activation and expression of 
chemokines/cytokines induced by DOTAP liposomes.  
(A) DOTAP triggers ERK activation through PI-3 kinase, inducing CC chemokine expression; (B) DOTAP also 
activates p38, which negatively regulates the ERK activation and also results in Th1 cytokine, such as IL-12 
expression. (C) Through unknown mechanisms, DOTAP induces co-stimulatory molecules expression and DC 
activation. NF-κB activation mediated by TLR is also plotted to compare with DOTAP induced signal transduction. 
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1.3.4 Investigation of current DOTAP/E7 cancer vaccine 
The encouraging results above prompted us to initiate a series of studies to assess whether 
cationic DOTAP liposome by itself could function as an immune stimulator such that an 
effective vaccine could be formulated. DOTAP/E7, which contains only an antigen and a 
cationic lipid was then prepared and studied in our lab. The physicochemical properties and anti-
cancer effect of DOTAP/E7 was compared side by side to those of LPD/E7, the previous vaccine 
version. A plausible mechanism to initiate DOTAP-mediated DC activation was also discussed. 
In addition, we further improved the vaccine formulation by incorporation of E7-
lipopeptide instead of the water-soluble native E7 peptide into the DOTAP liposome. The anti-
tumor activity of lipopeptide formulated in DOTAP liposome was more than twice as potent as 
that of native E7, likely owing to the increased peptide entrapment efficiency in the liposomal 
complex.  
Finally, we tested our vaccine formulation on the human model system. Instead of murine 
H-2Db restricted peptide, a HLA-A2 restricted CTL peptide epitope derived from E7 protein was 
formulated in the liposome. The results of DOTAP/hE7 vaccine obtained from HLA-A2 
transgenic mice or human blood cells were consistent to those collected from mouse model 
system. 
Overall, the report herein suggests that DOTAP/E7 is a potent therapeutic cervical cancer 
vaccine formulation which can be used in several clinical applications for the treatment of HPV-
related neoplasia. 
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2.0  A SIMPLE BUT EFFECTIVE CANCER VACCINE CONSISTING OF 
AN ANTIGEN AND A CATIONIC LIPID 
Developing a cancer vaccine with a potent adjuvant, which is safe for human use, remains to be 
an unmet challenge. In this study, we developed a simple, safe, yet efficient, peptide-based 
therapeutic cancer vaccine, DOTAP/E7 complex, which comprises only two molecules: a 
DOTAP cationic lipid and a peptide antigen derived from E7 oncoprotein of human 
papillomavirus (HPV) type 16. The anti-cancer activity of DOTAP/E7 against existing HPV 
positive TC-1 tumor was compared to that of our previous LPD/E7 formulation, which contains 
bacterial DNA CpG motifs. Tumor-bearing mice showed significant tumor inhibition following a 
single vaccination of either formulation at the optimal lipid dose, suggesting that DOTAP 
liposome alone can provide a potent adjuvant activity without plasmid DNA. E7 peptide 
formulated with DOTAP induced migration of activated dendritic cells (DC) to the draining 
lymph node (DLN) and efficiently generated functional antigen-specific CD8+ T lymphocyte 
responses. Accumulation of CD8+ tumor infiltrating T cells and apoptosis at tumor sites were 
observed after treatment with DOTAP/E7 complexes, which was also associated with a 
decreased amount of CD25+Foxp3+ regulatory T cells in treated animals. Reactive oxygen 
species (ROS) induced by DOTAP cationic lipid in DLN revealed a plausible mechanism of the 
initial interaction between DC and DOTAP. An adequate amount of ROS generation was 
apparently required for the initiation of the DOTAP/E7 vaccine action; however, an overdose of 
DOTAP induced a massive ROS production and apoptosis of DC in DLN, which led to a 
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diminished anti-cancer immunity. Overall, these results indicate that the cationic lipid DOTAP 
alone serves as an efficient vaccine adjuvant for the induction of a therapeutic, antigen-specific 
anti-cancer activity. 
2.1 INTRODUCTION 
The development of safe and effective therapeutic cancer vaccines for human use remains an 
urgent and unmet medical need. In order to elicit appropriate protective immune responses, the 
use of immunologic adjuvant to enhance and direct the immune response is required in a rational 
vaccine design [1]. For vaccines composed of synthetic peptide or subunit antigen, which are 
often unable to induce adequate immune responses, an appropriate adjuvant is necessary to 
improve the immune response and process a weakly immunogenic antigen. An ideal adjuvant for 
a therapeutic cancer vaccine should: increase the biological or immunological half-life of the 
vaccine antigen; improve antigen delivery and/or processing in the antigen presenting cells (APC) 
[2]; reduce the number of immunizations or the amount of antigen required for an effective 
vaccine [3]; induce the production of immunomodulatory cytokines that favor the development 
of Th1 immune responses to the vaccine antigen, thus promoting cell-mediated immunity 
including CTL [4]; and finally, overcome immune tolerance to tumor by inhibiting immune 
suppressive factors [5]. 
Previous work in our lab has led to the development of a liposome-based, nanoparticle 
delivery system, called LPD [6]. LPD, originally designed as a gene delivery system, is self-
assembled from cationic liposomes, polycations and plasmid DNA. LPD is also a novel vaccine 
adjuvant for stimulating both humoral and cellular immune responses [7]. Intravenous 
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administration of LPD potentiates efficient anti-tumor activity in a murine tumor model 24 JK, 
even when the formulation contained an empty, non-coding plasmid [8]. It was further correlated 
with its ability to induce Th-1 cytokines such as TNF-α, IFN-β and IL-12 and to the 
development of tumor-specific CD8+ cytotoxic lymphocytes [9]. The observed anti-tumor 
activity originates from the innate immunostimulatory activity of the unmethylated CpG motif, 
abundantly present in the plasmid DNA [10]. Cationic liposomes are capable of protecting 
plasmid DNA from extracellular degradation and thus more DNA enters the endosomal 
compartment where the toll-like receptor 9 (TLR9) is selectively expressed [11], [12]. However, 
cationic liposomes alone are relatively inert in terms of activating immune responses and there 
have been no studies so far to support that the cationic liposome by itself can serve as an efficient 
adjuvant [13], [14].  
Our previous studies have shown that a strong antigen-specific anti-tumor response was 
observed in mice, which received LPD particles loaded with an MHC class I-restricted peptide 
(RAHYNIVTF) epitope derived from the E7 protein of human papillomavirus (HPV) type 16 
[15], [16]. It induced an E7-specific CTL response, which contributed both to protective and 
therapeutic effects against E7-expressing TC-1 tumors, a murine model for human cervical 
cancer [17]. Recently, we have also investigated structure-specific immunomodulatory effects of 
cationic lipids on dendritic cells [18]. Our data suggest that some of the cationic lipids alone can 
activate dendritic cells toward expression of surface markers, CD80 and CD86. Moreover, we 
found that cationic liposomes, such as DOTAP, could stimulate DC, resulting in MAP kinase 
ERK activation and chemokine induction, such as CCL-2 [19]. The fact that cationic lipids alone 
could stimulate the antigen presenting cells was of high importance, since the 
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immunomodulatory adjuvant activities of LPD were initially thought to arise only by 
unmethylated CpG motifs of the plasmid DNA via the TLR9 [20], [21].  
The results prompted us to initiate a series of studies to assess whether cationic DOTAP 
liposome by itself could function as an immune stimulator such that an effective vaccine could 
be formulated. In the present study, we examined for the first time the immunological 
mechanism and anti-cancer effect of an efficient therapeutic cancer vaccine formulation, 
DOTAP/E7, which contains only an antigen and a cationic lipid. We describe herein the anti-
tumor activity of this simple vaccine. 
2.2 MATERIALS AND METHODS 
2.2.1 Lipids, reagents and murine tumor cell lines 
DOTAP and other lipids were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). 
Protamine sulfate was purchased from Sigma-Aldrich (St. Louis, MO, USA) and plasmid DNA 
(pNGVL3) was obtained from the National Gene Vector Laboratory (Ann Arbor, MI, USA). 
CpG ODN1826 was requested from IDT, Inc. (Coralville, IA, USA) and the complete Freund’s 
adjuvant (CFA) was purchased from DIFCO Laboratories (Detroit, MI, USA). Murine TC-1 
cells were kindly provided by Dr. T.C. Wu at Johns Hopkins University (Baltimore, MD, USA). 
TC-1 cells are C57BL/6 mouse lung epithelial cells transformed with HPV 16 E6 and E7 
oncogenes and the activated H-ras. BL6 are melanoma cells derived from C57BL/6. Both murine 
tumor cell lines were maintained in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) 
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supplemented with 10% fetal bovine serum, 100 units/ml penicillin, and 100 μg/ml streptomycin 
(Invitrogen).  
2.2.2 Peptide synthesis  
H-2Db restricted peptide RAHYNIVTF derived from HPV 16 E7 protein (amino acid 49-57) was 
synthesized and purified in Molecular Medicine Institute Peptide Synthesis Facility in the 
University of Pittsburgh. 
2.2.3 Preparation and characterization of DOTAP/E7 and other liposomal complexes  
Cell culture grade water (Cambrex, Walkersville, MD, USA) was used in all liposome 
preparation procedures. Briefly, lipid films were made in a glass vial by evaporating the 
chloroform solution under a steady stream of dry nitrogen gas. Traces of organic solvent were 
removed by keeping the films under vacuum with desiccators overnight. Lipid films were 
hydrated for 12 h by adding the required amount of water to make a final concentration of 10 
mg/ml. The suspensions were then sonicated in a bath-type sonicator for 10 min followed by 
extrusion (Hamilton Co., Reno, NV, USA) through 400, 200 and 100 nm membrane filters and 
were stored at 4°C before use. For the preparation of DOTAP/E7, the lipid film was hydrated 
with an aqueous solution of E7 peptide instead of water. LPD formulation comprises DOTAP 
lipid, protamine and plasmid DNA at a ratio of 8.6:0.6:1 (w/w/w). LPD was made as described  
[16] and the complex was allowed to stay at room temperature for at least 20 min prior to the 
injection.  
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The particle size and the zeta (ζ) potential of the liposomal complexes were measured 
following the manufacturer’s instruction using a Coulter N4 Plus particle sizer (Beckman Coulter, 
San Francisco, CA, USA) and a Zeta-Plus (Brookhaven Instruments, Corp., Holtsville, NY, 
USA). Peptide encapsulation was determined by the percentage of liposome-bound peptide. In 
brief, the unbound peptide from DOTAP/E7 and LPD/E7 was separated from the complex by a 
Microcon® centrifugal filtrate device (Millipore, Bedford, MA, USA) and the concentration of 
unbound peptide was measured by Micro BCATM protein assay kit (Pierce, Rockford, IL, USA). 
The efficiency of peptide encapsulation was determined as (1- % unbound peptide) and was 
reported as mean ± SD (n =3).  
2.2.4 Mice and immunizations 
All work performed on animals was in accordance with and permitted by our institutional 
IACUC. C57BL/6 female mice, 6-7 weeks old were purchased from Charles River Laboratories 
(Wilmington, MA, USA) and were used in all animal studies. Subcutaneous tumors were 
established by injecting TC-1 cells (105 cells) into the hair-trimmed flank of the mouse on day 0. 
On day 6, mice (n = 6-12) were injected subcutaneously (sc) at the opposite side of the flank 
with 150 μl of selected formulations containing 10 μg of the E7 peptide. The size of the tumor 
was measured using a caliper two or three times a week. Tumor size was determined by 
multiplying the two largest dimensions of the solid tumor.  
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2.2.5 Antibodies and flow cytometric analysis  
All anti-mouse antibodies used for flow cytometric analysis were purchased from BD 
Pharmingen (San Diego, CA, USA) or eBioscience, Inc. (San Diego, CA, USA). Spleen cells or 
lymph node cells were harvested and dissociated by incubating with 1 mg/ml collagenase 
(Sigma-Aldrich) for 20 min and passing through a 70 μm cell strainer (BD Biosciences). After 
removal of red blood cells (RBC), the cell suspensions were incubated with anti-CD16/CD32 
(24.G2) on ice for 15 min to block non-specific binding, followed by immunostaining with 
fluorescently conjugated antibodies to surface antigens for 30 min at 4°C. The following Abs 
were used: anti-CD3e (145-2c11), anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-CD11c (HL3), 
anti-CD25 (pc61.5), anti-CD80 (16-10A1), anti-CD86 (GL1) and anti-NK1.1 (pk136). Isotype 
control Abs were used to set the background for the surface Ab labels. Prior to staining 
intracellular molecules such as Foxp3 and IFN-γ, cells were fixed and permeabilized using the 
Cytofix/Cytoperm™ kit (BD Pharmingen) according to the manufacturer’s instruction. Cells 
were finally resuspended in 300 μl stain buffer and analyzed using a BD FACSCanto digital flow 
cytometer (San Diego, CA, USA).  
2.2.6 Tracking uptake of fluorescent DOTAP/E7 complexes in vivo  
The mice were sc injected with DOTAP/E7 containing 100 nmol total lipid with 0.05% (w/w) 
NBD-DOTAP. The draining lymph nodes (DLNs) were isolated at various time points after 
injection. Cell suspensions were stained with appropriate antibodies and analyzed by flow 
cytometry. Analysis gates were set on live cells based on the forward and side scatter 
characteristics.  
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2.2.7 Immunohistochemistry and TUNEL  
Solid TC-1 tumors were established as described and the mice were given treatments on day 6. 
On day 14, tumor samples were dissected and embedded in Tissue-Tek® OCT compound 
(Sakura Finetek, Torrance, CA, USA) followed by cryosection preparation. The samples were 
cut into 8 μm thick sections with a cryostat (Hacker Instruments & Industries Inc., Winnsboro, 
SC, USA). The sections were stained with FITC-conjugated anti-CD8 or anti-CD4 antibodies 
(Miltenyi Biotec Inc. Auburn, CA, USA) to determine tumor-infiltrating T cells. The samples 
were mounted on a coverslip using Vectashield® mounting solution (Vector Laboratories, Inc., 
Burlingame, CA, USA) containing DAPI to counterstain nuclei. Images of the sections were 
taken using a Leica SP2 confocal microscope.  
TUNEL assay was conducted using a TACSTM TdT Kit (R&D Systems, Minneapolis, 
MN, USA) and developed with DAB according to manufacturer’s instructions. Samples were 
imaged using a Nikon Microphot SA microscope. 
2.2.8 Analysis of Ag specific CTL and immune response  
Naïve C57BL/6 mice were immunized with 10 μg E7 peptide formulated in DOTAP liposomal 
formulations on day 0 and 7. For in vitro CTL assay, the mice were killed 7 days after the last 
immunization and spleen cells were isolated and dissociated. After RBC lysis, the total spleen 
cells (responder cells) were in vitro stimulated for 5 days with E7 peptide (10 μg/ml) in the 
presence of β-mercaptoethanol and 40 U/ml recombinant mIL-2 (R&D Systems) in complete 
RPMI-1640 medium. After 5-day of CTL expansion, responder cells were used as CTL effectors 
while TC-1 tumor cells were used as target cells in this assay. To discriminate between effectors 
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and targets, TC-1 cells were labeled with PKH-67 (Sigma-Aldrich) according to manufacturer’s 
instructions. The mixture of effectors and labeled targets were plated into 96-well U-bottom 
plates at various effector:target (E:T) ratios and the cell lysis reactions were carried out for 4 h at 
37°C. The cells were then harvested and stained with propidium iodide (Sigma Aldrich) prior to 
flow cytometric analysis. The percentage of E7-specific lysis was determined by the proportion 
of PI positive cells within the FL1 (PKH-67) positive region.  
In vivo CTL activity of E7-specific cytotoxic T cells was enumerated according to the 
protocol of Byers et al. [22] with minor modifications. In brief, spleen cells from syngenic mice 
were RBC lysed followed by pulsing with 10 μM E7 peptide or without peptide in complete 
medium for 1 h at 37°C. Both spleen cell populations were stained with equal amount of 2 μM 
PKH-26 (Sigma-Aldrich) according to manufacturer’s instruction. The peptide pulsed and 
unpulsed populations were loaded with 4 and 0.4 μM CFSE (Molecular Probe), respectively, at 
37°C for 15 min. The two cell populations were mixed together (1:1) before tail vein injection to 
the control or DOTAP/E7 immunized mice (107 cells per mouse injection). At 16 h after 
injection, spleen cells from the recipient mice were isolated and single cell suspension were 
prepared prior to flow cytometric analysis. The number of CFSEhigh and CFSElow population 
were determined and the in vivo E7 specific lysis percentage was enumerated according to a 
published equation [22].  
For the measurement of IFN-γ producing CD8+ T cells, spleen cells were isolated from 
the control or immunized mice 7-10 days after the last immunization. 2 × 106 spleen cells were 
incubated with 5 μg/ml E7 peptide or without peptide in the presence of 1 μl/ml of GolgiStopTM 
(BD Pharmingen) for 6 h. After washing with FACS buffer, cells were stained with Abs to 
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surface markers and intracellularly with IFN-γ mAb (XMG1.2) prior to analysis by flow 
cytometry.  
2.2.9 Analysis of ROS cytotoxicity in the DLN  
The mice were sc injected with DOTAP/E7 containing 0, 15, 100 or 600 nmol total lipid and the 
DLNs were isolated at a 2 h time point after injection for the analysis of ROS production. Single 
cell suspensions were prepared and incubated with 20 μM 2’, 7’-dichlorodihydrofluorescein 
diacetate (DCFH-DA) (Sigma-Aldrich) in serum free medium in the dark for 30 min at 37°C. 
The non-fluorescent DCFH-DA readily diffuses into the cells where it is hydrolyzed to become 
the polar derivative DCFH, which is oxidized in the presence of ROS to the highly fluorescent 2’, 
7’-dichlorofluorescein (DCF) [23]. The cells were quickly washed with pulse spin and 
immediately analyzed by flow cytometry. For determining cytotoxicity induced by the high dose 
of DOTAP lipid, DLNs from the immunized mice were collected at 10 h after injection, followed 
by subsequent staining with Abs to the surface markers. Cell suspensions were added with 
propidium iodide prior to flow cytometric analysis. The percentage of cell death of DC in the 
DLN was determined by the proportion of PI+ cells within the CD11c+ region.  
2.2.10 Statistical analysis  
Data were analyzed statistically using a two-tailed Student’s t-test. Data were considered 
statistically significant when the P value was less than 0.05. 
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2.3 RESULTS 
2.3.1 Cationic DOTAP liposome as a potent cancer vaccine adjuvant, which provides a 
major contribution toward the anti-tumor activity of LPD vaccine formulation  
Previous investigations by our group showed that LPD encapsulated with an MHC class I 
peptide epitope derived from HPV (type 16) E7 protein can generate a preventive as well as a 
therapeutic effect against the HPV16 E7 positive tumor cell line, TC-1 [17], [16]. However, there 
are concerns regarding LPD/E7 vaccine formulation such as the possible toxicity, which can be 
induced by a high dose of lipid-DNA complex (lipoplex) [24]. To assess the adjuvant activity of 
lipoplex, we examined anti-TC-1 tumor activity of LPD/E7 formulation at various DOTAP lipid 
concentrations. TC-1 tumor bearing mice sc received 10 μg E7 peptide formulated in LPD on 
day 6 post tumor inoculation (Fig. 2.1a). DOTAP lipid concentrations in LPD varying from 3 to 
600 nmol were investigated and the L:P:D weight ratio (8.6:0.6:1) was kept the same in all 
groups. The mice that received LPD/E7 containing the lowest amount of DOTAP (3 nmol) 
showed partial tumor inhibition (P < 0.05) compared to the untreated control group on day 23. 
LPD/E7 with DOTAP at 15 or 30 nmol exhibited an enhanced efficacy (P < 0.01), while LPD/E7 
with 75 or 150 nmol lipid showed the most significant tumor regression (P < 0.001). 
Interestingly, mice given high doses of LPD (300 or 600 nmol) did not show significant tumor 
inhibition.  
Upon receiving cationic lipoplex, bacterial DNA containing immunostimulatory CpG 
motif activates host innate immune response, which includes the induction of proinflammatory 
cytokines and immune cell activation, especially in human [25]. To avoid the drawbacks of CpG 
effect and to assess whether cationic lipid alone could function as a cancer vaccine adjuvant, we 
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have investigated a new formulation that only contains cationic DOTAP liposomes and the E7 
peptide. The new formulation, DOTAP/E7, without plasmid DNA and protamine sulfate, also 
exhibited anti TC-1 tumor effect (Fig. 2.1b). The tumor growth kinetics in mice treated with 
DOTAP/E7 was similar to that of the LPD/E7 formulation. Low dose of DOTAP (15 nmol) 
showed partial TC-1 tumor inhibition effect (P < 0.05) compared to the untreated control on day 
23, while DOTAP at 30, 150 or 300 nmol exhibited an enhanced efficacy (P < 0.01). DOTAP at 
75 nmol showed the most significant tumor regression effect (P < 0.001). Again, mice given a 
high dose of DOTAP (600 nmol) did not show anti-tumor activity, suggesting that DOTAP 
liposomes at a high dose might have induced a negative regulation to the immune response. In 
addition, DOTAP liposomes at optimal dose, but without E7 peptide, did not show significant 
inhibition, indicating that the anti-tumor effect was antigen specific. Anti TC-1 tumor activity of 
both DOTAP/E7 and LPD/E7 formulations was compared on day 23 by plotting the tumor size 
at each corresponding DOTAP lipid concentration (Fig. 2.1c). The data is pooled from three 
independent experiments and it is evident that these two dose response curves are almost 
identical to each other and no significant difference was found in any paired tumor size 
comparison. This result suggests that the DOTAP liposome is the major active ingredient in the 
LPD formulation to provoke immune response. Plasmid DNA and protamine are not necessary 
for the potent anti-tumor activity of the vaccine. We have also shown that low or non-detectable 
TNF-α production (<10 pg/ml) in the sera of mice injected with DOTAP/E7, indicating low 
toxicity of our vaccine formulation. Also, according to the bell-shape curves in Fig. 2.1c, the 
optimal dose of DOTAP liposome is around 100 nmol and both low and high doses compromise 
its anti-tumor activity. This finding tempted us to investigate the role of DOTAP as a vaccine 
adjuvant in supporting the anti-cancer activity of DOTAP/E7. 
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Figure 2.1. Kinetics of TC-1 tumor growth in mice treated with LPD/E7 or DOTAP/E7 formulation.  
A, C57BL/6 female mice of 7 weeks old (n = 8-12) were injected sc with TC-1 tumor on day 0. On day 6, the mice 
received 10 μg E7 peptide formulated in LPD at various DOTAP lipid concentrations. The untreated mice were used 
as a negative control. B, On day 6 post TC-1 inoculation, the mice received treatment of 10 μg E7 peptide 
formulated in DOTAP liposomes at various lipid concentrations. Tumor sizes were measured with calipers and 
determined by multiplying the two largest dimensions of the tumor. Tumor size of each group on day 23 was 
compared to the untreated control group and was analyzed statistically (*P <0.05, **P < 0.01, ***P <0.001). C, The 
anti TC-1 tumor activity of the formulations DOTAP/E7 and LPD/E7 was contrasted on day 23 by comparing the 
tumor size at each corresponding DOTAP lipid concentration. No statistically significant differences in tumor size 
were found between the two groups. D, Anti-cancer activity of DOTAP/E7 was compared to that of other cationic 
lipids (DOEPC and DOTMA), an anionic lipid (DOPG), CFA and CpG ODN1826. Tumor-bearing mice (n = 6-12) 
received a single treatment on day 6 after tumor inoculation. TC-1 tumor sizes were measured and analyzed 
statistically. 
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To assess the efficacy of DOTAP/E7-induced immune response compared to other 
adjuvants, tumor-bearing mice were treated on day 6 with E7 peptide formulated in DOTAP, two 
additional cationic liposomes, DOEPC and DOTMA, an anionic lipid, DOPG, CFA and CpG 
ODN1826. In Fig. 2.1d, the mice that received the above formulations showed significantly 
smaller tumor sizes compared to the untreated group on day 26, except for those that received 
DOPG/E7, which did not show tumor regression. More importantly, the mice that received 
DOTAP/E7 formulation exhibited a better anti-cancer activity (P <0.01) compared to those that 
received CpG/E7 or CFA/E7 formulations.  
2.3.2 Physical properties of DOTAP/E7 complexes and the efficiency of E7 peptide 
entrapment in the liposome 
DOTAP liposomes and DOTAP/E7 particles were prepared at 0.1 mM and their particle sizes 
and zeta (ζ) potentials were characterized. The particle size of DOTAP/E7 was not significantly 
changed compared to that of the plain DOTAP liposome, which was 100 ± 24 nm in diameter. 
Also, the zeta potential of DOTAP/E7 particle was similar to that of DOTAP liposomes (43.5 ± 
7.8 mV), indicating that the particle remains positively charged after changing the composition 
of DOTAP lipid and peptide. E7 peptide entrapment efficiency in DOTAP/E7 particles, which 
was determined by the percentage of liposome-bound E7 peptide was around 32 ± 4% in both 
DOTAP/E7 containing 100 or 600 nmol total lipids, whereas DOTAP/E7 with 15 nmol lipid 
showed a lower entrapment efficiency (17 ± 4%).  
 40 
2.3.3 DOTAP/E7 particles are mainly taken up by dendritic cells after sc injection, 
resulting in the migration of activated DC to the DLN 
Previous studies from our lab describe the ability of cationic liposome to activate mouse bone 
marrow dendritic cells in vitro [18], and the production of IL-12 by BMDC increases in response 
to DOTAP concentration (data not shown). The findings prompted us to hypothesize that DC, the 
professional APC, would be the direct responder after sc injection of DOTAP/E7 vaccine in vivo. 
To address the effect of DOTAP/E7 on DC activation and migration to the DLN, naïve mice 
were injected sc with DOTAP/E7 containing 0.5% (w/w) NBD-DOTAP at the flank. DLNs were 
harvested and analyzed by flow cytometry at different time points, post injection. The numbers 
of CD11c+ cells among total lymph node cells were increased more than 2.5-fold compared to 
the untreated at 4 h after NBD-DOTAP/E7 injection (Fig. 2.2a, b). The expression of 
costimulatory molecule CD86 on the NBD+ cells was investigated. NBD+ cells demonstrated 
high levels of CD86 (Fig. 2.2c, d), indicating that sc injection of DOTAP prompted DC 
activation. NBD uptake by other cell types such as T lymphocytes was also investigated by co-
staining with anti-CD3, CD4 and CD8 Abs. The dot plots in Fig. 2.2e, f were gated on the CD3+ 
population. Neither of the CD8+ or CD8− cells showed NBD uptake after NBD-DOTAP injection. 
The results clearly demonstrated that NBD-DOTAP is mainly taken up by DC (80%) soon after 
immunization and DOTAP induces migration of activated DC to the DLN, resulting in DC-T cell 
interactions and eliciting T cell responses.  
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 Figure 2.2. Subcutaneous injection of DOTAP induces DC activation and migration to the DLN.  
Naïve mice (n = 4–6) were injected sc with PBS control (A, C, E) or DOTAP/E7 containing 100 nmol total lipid 
with 0.5% NBD-DOTAP (B, D, F). At 4 h after the injection, DLNs were prepared and stained with appropriate 
antibodies to surface markers. The co-expression of NBD and CD11c (A, B) or CD86 (C, D) was analyzed within 
total lymph node cells, whereas the co-expression of NBD and CD8 (E, F) were gated and analyzed within the CD3+ 
population. The numbers represented the percentages of cells in the quadrants. 
2.3.4 Tumor infiltrating T lymphocytes were found in mice treated with DOTAP/E7 at an 
optimal lipid dose 
To understand whether the optimal DOTAP/E7 formulation induces migration of T lymphocytes 
to the tumor microenvironment, we performed immunohistochemistry staining on the frozen 
tumor tissues to examine tumor-infiltrating T lymphocytes (Fig. 2.3). TC-1 tumor-bearing mice 
were treated with PBS, DOTAP/E7 (containing 15, 100 or 600 nmol lipid) or LPD/E7 as 
described. On day 14 after TC-1 inoculation, solid tumors were harvested for preparation of 
cryosection and immunostaining. An increased amount of CD8+ T lymphocytes (∼5%) were 
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found in mice that received LPD/E7 (data not shown) or DOTAP/E7 at the optimal lipid dose 
(100 nmol, Fig. 2.3b) compared to untreated (Fig. 2.3a) or those received DOTAP overdose 
(600 nmol, Fig. 2.3c). A similar result was found for CD4+ T cells; around 2% of tumor 
infiltrating CD4+ T lymphocytes were found in mice that received an optimal dose of DOTAP 
(Fig. 2.3e), but not in the untreated or overdosed group.  
 
 
Figure 2.3. Tumor infiltrating T-lymphocytes were found in mice that received DOTAP/E7 at an optimal dose. 
TC-1 tumors were established as described and were left untreated or given treatment on day 6. Solid tumors were 
dissected on day 14 and examined for infiltrating lymphocytes. FITC conjugated anti-CD8 (A, B, C) and anti-CD4 
(D, E, F) antibodies were used to determine tumor infiltrating T cells followed by counterstaining with DAPI. 
Representative tumor sections from groups of three mice were examined as described and imaged by confocal 
microscopy. TUNEL assay was conducted to detect cell apoptosis in the tumor sections (G, H, I). 
 
 43 
TUNEL assay for determining apoptotic cells was also performed in tumor cryosections. 
A TUNEL-positive reaction was observed in the condensed and fragmented nuclei of the tumor 
cells after the mice were treated with LPD/E7 (data not shown) or DOTAP/E7 at an optimal dose 
(Fig. 2.3h) compared to the untreated (Fig. 2.3g) and overdosed group (Fig. 2.3i), which 
exhibited normal and vital tumor cells. Similar result, from Hematoxylin and Eosin staining (data 
not shown), showed that tumor necrosis was found only in the mice treated with E7 formulated 
with an optimal dose of DOTAP. The results indicate that the eliciting CD8+ T lymphocytes 
were attracted to the tumor micro-environment and tumor cells were undergoing apoptosis or 
necrosis upon DOTAP/E7 treatment. 
2.3.5 Decreased amount of Treg population in DOTAP/E7 treated mice was correlated 
with the anti-tumor activity  
Despite intense recent interest, the suppressive mechanisms of regulatory CD4+CD25+ T cells 
(Tregs) remain poorly understood. Tregs are thought to dampen functional T cell immunity to 
tumor-associated antigens and to be the main obstacle, hampering successful immunotherapy and 
active vaccination [26]. It becomes necessary to monitor and characterize both effector and Treg 
responses in hosts that receive candidate tumor vaccine [5]. In Table 2.1, ten representative 
experiments are summarized on the phenotype analysis for the spleen cells obtained from tumor-
bearing mice after vaccine treatment. The population of CD4+ T cells was significantly increased 
in spleen cells from mice that received DOTAP/E7 treatment with an optimal lipid dose. The 
percentage of CD4+ within the total lymphocyte population was shown. An increased amount of 
CD8+ T cells was also observed (data not shown).  
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Table 2.1. Treg subpopulation profile in spleen cells obtained from  
tumor-bearing mice after treatments with liposomal vaccine 
** p< 0.01, *** p< 0.001 (n = 10 per group)
7.4 ± 0.1%
9.5 ± 0.9%
7.2 ± 0.2%
8.4 ± 0.2%
9.5 ± 0.5%
CD25+ Foxp3+ in 
CD4+ cells
11.0 ± 0.1%26.8 ± 2.2%LPD/E7 100 nmol
12.0 ± 1.0%21.7 ± 1.3%DOTAP/E715 nmol
14.3 ± 1.3%22.1 ± 2.1%DOTAP/E7600 nmol
11.4 ± 0.2%25.1 ± 2.4%DOTAP/E7100 nmol
13.1 ± 0.1%18.8 ± 2.9%PBStreated
Foxp3+ in 
CD4+ cells
CD4+ in 
lymphocytes
***
**
** ***
** **
 
 
In addition, a significant decrease in the Treg population (CD4+Foxp3+ and 
CD4+CD25+Foxp3+) was found in this treatment group, which is correlated with the results of 
anti-tumor activity. Similar results were observed in the LPD/E7 treated group. On the other 
hand, spleen cells collected from mice that received overdosed DOTAP did not show significant 
difference in the Treg population compared to the untreated tumor bearing mice. This result 
indicates that there is evidence for preferential expansion of T effector cells relative to Tregs 
after the treatment of DOTAP/E7 vaccine at an optimal lipid dose.  
2.3.6 In vitro CTL-mediated and NK cell-mediated cytotoxicity 
Since cytotoxic T lymphocytes (CTL) are most capable of killing tumor cells, vaccines that 
induce these immune responses are important for eradicating tumor growth or preventing cancer 
recurrences. To evaluate whether vaccination by DOTAP/E7 would be suitable for inducing a 
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primary CTL response, we prepared effector cells by collecting spleen cells from immunized 
mice at 1 week after the last immunization, followed by in vitro culture with 5 μg/ml E7 peptide 
for 5 days. As depicted in Fig. 2.4a, a cytotoxicity assay was carried out by incubating effector 
cells with PKH-67 labeled TC-1 target cells for 4 h and the percentage of killing was revealed by 
adding propidium iodide to label the killed cells, followed by flow cytometric analysis.  
Spleen cells recovered from mice that received DOTAP/E7 at an optimal lipid dose 
exhibited significant CTL activity against TC-1 cells, while mice that received LPD/E7 or 
DOTAP overdose showed a moderate killing effect (Fig. 2.4a). We confirmed that the killing 
effect was E7-specific by incubating effector cells with E7-negative BL6 cells as targets, and 
negligible cytotoxicity was found. In addition to CTL-mediated killing, we also investigated 
natural killer (NK) cells-mediated cytotoxicity (Fig. 2.4b). NK cells are reported as being able to 
destroy tumor cells without deliberate immunization or activation and also play an important role 
in the innate immune response to interact with dendritic cells [27], [28]. In comparison with the 
PBS control, spleen cells directly harvested from mice that received liposomal peptide vaccines, 
without in vitro restimulation process, exhibited significant killing of YAC-1 cells, an NK 
susceptible target. The data indicated that DOTAP/E7 formulations were capable of stimulating 
NK cells, which were present in the effector cell population. 
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 Figure 2.4. Analysis for CTL-medicated and NK-mediated cytotoxicity by flow cytometry.  
A, E7-specific CTL clones were prepared and expanded as described. After 5 days in vitro restimulation with E7 
peptide, effector cells were incubated with PKH-67 labeled TC-1 target cells at the indicated effector:target ratio for 
4 h at 37°C. BL-6 was used as a non-specific target cell control. Percentage of E7-specific killing was determined by 
the proportion of PI positive cells within the gating of PKH-67 positive target cells. Statistical analysis was 
calculated by comparing treatment group and control group at 100:1 E:T ratio (*P <0.05, **P < 0.01, n =5). B, On 
day 7 after the last immunization, splenocytes from each group were harvested and incubated with PKH-67 labeled 
YAC-1 cells at the indicated E:T ratio for 4 h at 37°C. Percentage of killing was determined as described. Statistical 
analysis was done by comparing the treatment group and control group at 33:1 E:T ratio (*P <0.05, n =3). 
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2.3.7 CD8+ T cells elicited by DOTAP/E7 are functionally active in vivo  
In vitro CTL was measured after expansion of the splenocytes with antigen in vitro; however, 
there is a possibility of over- or underestimating the CTL function due to the restimulation 
process. Thus, we evaluated whether the observed in vitro CTL was also relevant in vivo (Fig. 
2.5a). A mixture containing equal amounts of E7-pulsed CFSEhigh and unpulsed CFSElow spleen 
cells from a syngenic donor was injected iv into the mice, 1 week after the last DOTAP/E7 
immunization. The specific lysis of target cells was analyzed by flow cytometry at 16 h after 
adoptive transfer. The percentage of E7-specific killing from mice that received an optimal dose 
of DOTAP/E7 or LPD/E7 was more than 65%, while in the groups that received DOTAP at low 
dose and overdose showed only 15 and 25% specific killing, respectively (Fig 2.5b).  
IFN-γ secreted by activated T cells or NK cells play an important role in Th1 type 
immune response as well as inducing CTL response [29]. To assess whether the functional CD8+ 
T lymphocytes induced by DOTAP/E7 vaccination would be able to produce the essential 
cytokine, spleen cells from control or immunized mice were isolated at 1 week after the final 
immunization and incubated with 5 μg/ml E7 peptide (Fig. 2.5c, lower panel) or without peptide 
(Fig. 2.5c, upper panel) for 6 h followed by intracellular staining of IFN-γ. The numbers 
represent the percentage of CD8 and IFN-γ double positive cells within the CD8+ population. As 
depicted in Fig. 2.5d, the numbers of IFN-γ producing CD8+ cells were significantly higher in 
mice that received E7 formulated in an optimal lipid dose of DOTAP and LPD than the control 
mice. The IFN-γ production by the CD8+ cells was in an E7-specific manner. These results show 
that DOTAP at an optimal dose is a potent vaccine adjuvant for the induction of CTLs as well as 
generation of IFN-γ producing CD8+ T lymphocytes in the systemic lymphoid organ.  
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 Figure 2.5. Immunization with E7 peptide formulated in DOTAP adjuvant elicits functional CD8+ T cells.  
A, C57BL/6 mice were immunized sc with 10 μg E7 peptide formulated in DOTAP at low, optimal, overdose or in 
LPD. Seven days after the last immunization, representative mice were injected iv with an equivalent amount of E7-
pulsed (labeled with 4 μM CFSE) and non-pulsed (labeled with 0.4 μM CFSE) spleen cells from a syngenic donor. 
The spleen cells were harvested from the recipient mice 16 h later and the proportion of the CFSEhigh and CFSElow 
cells were analyzed by flow cytometry. B, Percentage of specific anti-E7 killing was compared to that of the 
untreated control (n = 4) and was statistically analyzed by t-test (P <0.01). C, IFN-γ production by CD8+ cells after 
in vitro stimulation with E7 peptide. The total spleen cells from immunized cells were stimulated with 5 μg/ml E7 
peptide for 6 h, followed by subsequent staining with surface CD8 marker and intracellular IFN-γ prior to FACS 
analysis. The numbers shown on contour plots represent the percentage of CD8+IFNγ+ T cells gated on total CD8+ 
cells. Representative figures in the four experiments performed. D, The numbers of CD8+IFN-γ+ cells per 104 CD8+ 
T cells were shown as mean ± SD and were compared to that of the untreated control (n =4, **P <0.01). 
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2.3.8 ROS production induced by DOTAP liposome  
Reactive oxygen species (ROS), which has been regarded as a harmful signal, plays an important 
role in DC activation as well as antigen presentation to the T cells [30]. Our results demonstrated 
that DOTAP/E7 complexes were mainly taken up by DC in the DLN, and high dose DOTAP 
dramatically decreased the antigen-specific T cell responses. Since high levels of ROS generated 
in cells lead to cell death [31], we hypothesized that a high dose of DOTAP lipids may lead to 
massive ROS production in DC in the DLN, resulting in cell death of DC. To test out the 
hypothesis, we measured ROS levels induced by DOTAP/E7 in the DLNs at 2 h after sc 
injection. For characterization of DC in the DLN, large granular cells were gated and analyzed 
by flow cytometry. In Fig. 2.6a, cells from mice that received DOTAP 15 nmol exhibited a basal 
level of ROS production (<5%), whereas cells from mice injected with DOTAP at an optimal 
dose produced relatively higher levels of ROS (20%). Strikingly, a majority of large granular 
cells (80%) from the DOTAP 600 nmol group showed positive ROS signal.  
The subsequent question was whether the raised ROS induced by a high dose of DOTAP 
lipid triggered DC toward cell death. At 10 h post sc injection, DLNs were harvested and 
analyzed for cell death by flow cytometry. The percentage of cell death (propidium iodide 
positive) within the CD11c+ population showed positive correlation with the lipid dose as well as 
with the level of ROS production shown in Fig. 2.6b. The percentage of cell death in the DC 
population was twice as high for the group injected with DOTAP overdose compared to the 
group of untreated control. Also shown in Fig. 2.6b are the numbers of live CD11c+ cells per 105 
lymph node cells as a function of the dose of DOTAP lipid. The mice that received DOTAP/E7 
with lipid 100 nmol exhibited the highest amount (P <0.01) of live DC among all treatment 
groups. Indeed, the DLN weighed larger at 2 days after the mice received the optimal 
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formulation than other groups. Collectively, the results indicate that ROS toxicity induced by 
high dose DOTAP may cause cell death in DC. 
 
 
Figure 2.6. High dose of cationic DOTAP liposome induces ROS production, resulting in cell death in DC.  
A, DLNs from mice (n = 4) that received injection sc of DOTAP/E7 containing 0, 15, 100 or 600 nmol lipid were 
isolated 2 h after the injection. The total lymph node cells were incubated with DCFH-DA at 37°C for 30 min prior 
to the flow cytometric analysis. Large granular cells were gated and analyzed for the expression of ROS, where the 
fluorescent product DCF was generated in the presence of ROS. The relative percentages of cells with positive ROS 
signals are listed. B, Cytotoxicity in the DLN was measured by collecting cells at 10 h after DOTAP/E7 injection by 
flow cytometry. The relative percentages of dead cells (PI+) in DC (open square) and the numbers of live DC per 105 
LN cells (bars) were shown and compared with that of the untreated control by paired Student’s t test (**P <0.01). 
 
Since DOTAP-induced ROS signal initiates the vaccine mechanism owing to the 
interaction of DC and the lipid, we found that the anti-cancer activity can be diminished by co-
formulation of an inert lipid, DOPC with DOTAP/E7. As shown in Fig. 2.7, DOTAP at the 
optimal dose could induce the maximal vaccine activity and the desirable ROS content. However, 
both activities were significantly reduced when the same amount of DOTAP was diluted with an 
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inert neutral lipid, DOPC (1:5 dilution). In other words, the charge density of the cationic lipid 
could be an important parameter to ROS generation and the anti-cancer activity of the vaccine 
could be abolished by addition of an inert lipid. 
 
 
Figure 2.7. ROS production in DLN was diminished by co-formulation of an inert neutral lipid, resulting in 
decreased anti-tumor activity of the vaccine.  
ROS production in DLN was measured 2 h after receiving sc DOTAP/E7, DOPC/E7 or DOTAP/DOPC/E7 (mole 
ratio of DOTAP/ DOPC = 1/ 5) formulation as described. Large granular cells were gated and the relative 
percentage of ROS positive population are shown (open square). TC-1 tumor bearing mice were treated with the 
corresponding vaccine formulation on day 6 and tumor sizes (bars) on day 23 were measured and compared between 
each group. **P < 0.01 was found for the comparison between DOTAP/E7 and DOTAP/DOPC group by paired 
Student’s t test (n = 4-6). 
 
2.4 DISCUSSION  
As shown in the data of this report, we have demonstrated that the majority of the adjuvant 
activity of LPD comes from the DOTAP liposome and, for the first time, we have shown that 
cationic lipid alone is sufficient for a cancer vaccine adjuvant. Indeed, upon receiving the 
optimal lipid dose of DOTAP/E7, the particles were mainly taken up by DC, the major 
professional antigen presenting cells. The initiation of DC activation and migration to the DLN 
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facilitates immune responses against antigen-specific TC-1 tumor. Functional CD8+ T 
lymphocytes were generated upon receiving DOTAP/E7 vaccine. The size of the tumor 
decreased and the tumor exhibited enhanced apoptosis, likely owing to the increasing number of 
infiltrating T cells in the tumor microenvironment. According to the bell-shaped dose response 
curve in Fig. 2.1c, the rising arc is very steep, indicating that DOTAP as a vaccine adjuvant is so 
potent that EC50 is as low as about 15 nmol per injection. Herein, we have demonstrated that 
DOTAP/E7 formulation is truly a simple, safe, yet very efficient, therapeutic vaccine against pre-
existing HPV positive tumor.  
The E7 peptide RAHYNIVTF (amino acid 49-57) is positively charged and somewhat 
hydrophobic. The association of the peptide with the cationic liposomes must be due to 
hydrophobic interaction, because the percent encapsulation far exceeded what could be expected 
from the internal volume of the liposomes [32]. The suboptimal anti-cancer effect observed when 
low dose of lipids were used (i.e., 15 nmol DOTAP per dose) might be due to the insufficient 
number of vehicles to carry the required antigen to the lymphoid organs.  
Merck’s HPV vaccine, GARDASIL™, which is a preventive vaccine against HPV 
infection, is already available in the market. It contains HPV virus-like particles (VLPs), which 
mimic infectious virions in structure and morphology [33], [34] and potently induce high titered 
neutralizing antisera, even in the absence of any adjuvant [35], [36]. However, VLP vaccine is 
not likely to be active in treating established cervical cancer because the HPV coat proteins, 
which are major components of VLP, are not expressed in the cervical cancer cells. Our vaccine 
contains an epitope peptide of E7, which is expressed in the transformed cervical cells and can 
thus induce therapeutic immunity.  
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A great variety of experimental adjuvants are available for use in animals and some of 
them have been tested in clinical trials. They include several water-in-oil emulsions, liposomes 
and other chemical adjuvants [37]. However, only influenza virosomes [38] and Chiron’s MF59 
[39] have already been launched into the market, in addition to aluminum salts. Similar to 
cationic liposome, the submicron emulsion-based adjuvant, MF59, is internalized by dendritic 
cells [40]. It stimulates a variety of immune activities that lead to high antibody and T-cell 
reactions against co-delivered antigens. However, according to the clinical trial report on HSV 
and influenza vaccines [41], [42], evidence from animal models suggests that the MF59 adjuvant 
enhances neutralizing antibodies rather than T-cell responses [43]. Therefore, DOTAP liposome 
as a vaccine adjuvant is different from MF59 in that it generates a strong cell-mediated immune 
response, as shown by our data. We have compared the adjuvant activity of DOTAP with those 
of two other well-known adjuvants, i.e., CpG ODN and CFA. As shown in Fig. 2.1d, DOTAP 
compares favorably with them.  
Some recently developed adjuvants such as MPL [44] and CpG ODN [12] were meant to 
initiate innate immunity by triggering toll-like receptors (TLR) on dendritic cells and 
macrophages, thus inducing the production of NF-κB and inflammatory responses. We have 
previously demonstrated that DOTAP cationic lipid was unable to enhance the expression of NF-
κB, suggesting that stimulation of dendritic cells by cationic lipids is signaled through an NF-κB 
independent mechanism [16]. Thus, cationic liposomes could belong to a unique class of 
adjuvants with an improved safety profile.  
DOTAP/E7, the therapeutic cancer vaccine described in this report, contains only two 
molecules, i.e., an antigen and a carrier. In addition to the delivery of the E7 peptide to the 
cytoplasm of the APC such DC, DOTAP must also lead DC to activation and maturation. To 
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elucidate the mechanism of DOTAP as vaccine adjuvant, we have demonstrated that the ability 
of cationic lipids to activate DC depends on the structure of the cationic lipid. Cationic lipids 
with a quaternary ammonium group are more potent than those with a tertiary ammonium group 
[18]. More recently, we have reported that DOTAP and other active cationic lipids can activate 
MAP kinase ERK and p38 pathway [19] in DC, resulting in chemokines and cytokines 
production, especially CCL2. All of the preceding results support our hypothesis that DC plays 
an important role in response to DOTAP stimulation.  
The ROS has been implicated in innate immune response and T cell activation [30], [45], 
and excess of ROS production leads to cell death [46], [47]. We have shown in this report that 
ROS was induced by DOTAP in cells in the DLN and a high dose of DOTAP lipid led to killing 
of DC. Indeed, Iwaoka et al. have shown that cationic liposomes can induce ROS in 
macrophages in vitro [31]. Data shown in Fig. 2.6a clearly demonstrate that DOTAP was 
capable of generating ROS signal in vivo in the DLN after sc injection of DOTAP/E7 complexes. 
The same data also suggest that excess ROS generated by a high dose of DOTAP leads to 
enhanced death of DC. There might be other possible reasons related to the loss of anti-cancer 
activity by overdose of DOTAP/E7; however, the decreased amount of activated APC in the 
DLN should definitely play an important role in the observed decrease in the lymphocyte 
infiltration (Fig. 2.3), antigen-specific CTL activities and IFN-γ production (Figs. 2.4 and 2.5) 
and, most importantly, the anti-tumor activity (Fig. 2.1) at the high vaccine dose. On the other 
hand, a desirable level of ROS production is required since DOTAP-induced ROS is probably 
the initial signal to mediate the subsequent signal transduction, such as the ERK and p38 MAP 
kinases, necessary for the vaccine activity [19]. We have demonstrated the importance of the 
density of the cationic lipid to the anti-cancer activity in Fig. 2.7 where we showed that both 
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ROS generation and anticancer activity could be diminished by co-formulation of an inert, 
neutral lipid, DOPC with DOTAP/E7. The result indicates that the simple cationic DOTAP/E7 
formulation is not just a sufficient, but also a necessary, vaccine formulation for the treatment of 
cancer.  
A high dose of DOTAP seems capable of stimulating CTL, in Fig. 2.4a, using a 
traditional assay method, which requires in vitro stimulation of responder T cells with the 
antigen for 5 days. We cannot rule out the possibility that the true functionality of CD8+ cells 
was overestimated after in vitro expansion of the subset cells. An in vivo CTL result (Fig. 2.5a) 
gave us a better estimation of the functionality of CD8+ T cells elicited in the mice and the data 
showed that a high dose of DOTAP does not generate sufficient CTL in vivo. Although DOTAP 
at high dose could also generate a good NK response toward non-specific killing (Fig. 2.4b), the 
effect contributed little to the anti-tumor activity. It is not clear, at present, the role that NK cells 
play in the overall anti-tumor activity induced by DOTAP/E7. We have previously shown that 
the IFN-γ activity in the splenocytes of mice treated with LPD/E7 was independent of NK, since 
mice injected with NK1.1 antibody to eliminate the NK activity showed unchanged IFN-γ 
activity (Dileo et al., unpublished data). Mice injected with DOTAP alone without E7 did not 
show significant anti-tumor activity (Fig. 2.1b), suggesting that the antigen independent 
component was minor.  
T regulatory cells (Tregs) were initially described by Gershon et al. [48, 49] in the 1970s 
and were called suppressive T cells. Recent studies have explored the role of CD4+CD25+ Tregs 
in the suppression of tumor immunity in several murine models as well as in cancer patients [50]. 
The frequency of Treg population increases in the peripheral blood of cancer patients [51]. They 
are also enriched among the tumor infiltrating lymphocytes and in the DLNs [52]. Also, 
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accumulation of Treg in tumor-associated tissue predicts poor prognosis or survival [5]. 
Although the detailed mechanism of how Treg dampens normal T-cell immunity is not well 
understood, it has been reported that the anti-tumor activity is enhanced by using anti-CD25 
antibody to block Treg cells [53]. Indeed, it has become apparent that it will be necessary to 
monitor and characterize both the effector and Treg responses in patients that receive candidate 
human tumor vaccines [5]. In the present studies, we found a correlation of the anti-tumor 
activity of the DOTAP/E7 (Fig. 2.1b) with the reduction of Treg cells (Table 2.1). It was evident 
that the reduced anti-tumor activity of DOTAP/E7 at a high dose was associated with a higher 
level of Tregs, probably owing to the excess ROS production and cell death in DC. However, we 
do not have direct evidence to show that a high dose of DOTAP increases Tregs subpopulation.  
In summary, the promising features of the DOTAP/E7 formulation, which contains only 
two molecules, include the safety and stability of the complexes and the abilities to elicit DC 
activation, generate antigen-specific CTL, as well as to inhibit an established tumor after a single 
dose of immunization. It also lends itself to the mechanistic studies of how DC can be activated 
by cationic lipids and how liposomes deliver the peptide antigen to DC. Although the dose of 
cationic DOTAP lipid as a vaccine adjuvant should be carefully studied before going to the 
clinical trial, it possesses great potentials that deserve further studies. 
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3.0  INDUCTION OF CYTOTOXIC T-LYMPHOCYTES AND ANTI-TUMOR 
ACTIVITY BY A LIPOSOMAL LIPOPEPTIDE VACCINE 
We have previously described a simple yet effective liposome-based therapeutic vaccine, 
DOTAP/E7, which contains only two molecules, the cationic lipid DOTAP and a peptide antigen 
derived from the E7 oncoprotein of human papillomavirus (HPV) type 16. In the current report, 
we have improved the vaccine formulation by incorporation of E7-lipopeptide instead of the 
water-soluble native E7 peptide into the DOTAP liposome. The lipopeptide consists of an N-
terminal α or ε-palmitoyl lysine connected to the E7 peptide via a dipeptide Ser-Ser linker. The 
DOTAP/E7-lipopeptide vaccine exhibited an enhanced functional antigen-specific CD8+ T 
lymphocyte response in vivo compared to the previous DOTAP/E7 formulation. More 
importantly, the cytotoxic T cells induced by the DOTAP/E7-lipopeptide vaccine could 
efficiently eliminate an existing HPV positive TC-1 tumor. The anti-tumor activity of lipopeptide 
formulated in DOTAP liposome was more than twice as that of native E7, likely owing to the 
increased peptide entrapment efficiency in the liposomal complex. Our results also showed that it 
is essential to have the dipeptide spacer sequence between E7 peptide and the attached fatty acid 
to achieve a full immune response. Overall, the improved DOTAP/E7-lipopeptide vaccine 
described herein showed a significantly enhanced therapeutic effect for the treatment of a 
cervical cancer model. 
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3.1 INTRODUCTION 
Liposomes have been extensively used for delivering small molecular weight drugs [1], plasmid 
DNA [2], oligonucleotides [3], proteins [4, 5] and peptides [6]. From a safety standpoint, a 
liposomal vehicle as a non-viral vaccine carrier has been regarded as a preferable strategy 
compared to traditional immunizations using live attenuated vaccines or viral vectors such as 
vaccinia or influenza virus [7, 8]. Recent studies from our group have led to the development of 
a simple yet effective peptide-based liposomal vaccine, DOTAP/E7 complex, which consists 
only two molecules, the cationic lipid DOTAP and a peptide antigen which is derived from E7 
oncoprotein of human papillomavirus (HPV) type 16. The DOTAP/E7 formulation was able to 
induce both preventative and therapeutic anti-tumor effects against HPV positive TC-1 tumor in 
a mouse model. Our results have demonstrated for the first time that the cationic liposome alone 
not only plays the role of a carrier to deliver the peptide antigen to the antigen presenting cells 
(APC), but also serves as a potent vaccine adjuvant to stimulate immune responses and initiate 
DC-T cell interactions [9, 10]. 
There has been considerable interest in developing lipopeptide formulations for both 
humoral and cellular immune response. This is in contrast to the native synthetic peptides which 
are poorly immunogenic. Peptides linked with mono- or multi- palmitic acid are capable of 
producing antigen specific cytotoxic T lymphocyte response against infectious diseases such as 
HIV [11, 12], HBV [13] and malaria [14] and several clinical trials are investigating this effect 
[15, 16]. However, lipopeptides have limited solubility and require a means for solubilization. 
Since liposome is a good carrier for lipophilic drugs, we investigated the possibility of 
formulating a lipopeptide antigen in the DOTAP liposomes. Our results showed significantly 
improved immunogenic activity of the lipopeptide as compared to the original E7 peptide. We 
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have also evaluated the anti-tumor activity of the E7-lipopeptide in DOTAP liposome in the TC-
1 cervical cancer model in mice. 
3.2 MATERIALS AND METHODS 
3.2.1 Lipids, reagents and murine tumor cell lines 
DOTAP was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Murine TC-1 cells were 
kindly provided by Dr. T.C. Wu at Johns Hopkins University (Baltimore, MD). TC-1 cells are 
C57BL/6 mouse lung epithelial cells transformed with HPV 16 E6 and E7 oncogenes and the 
activated H-ras. RMA-S, a mouse lymphoma cell line, was kindly provided by Dr. J. Frelinger at 
University of North Carolina at Chapel Hill. Both H-2b murine tumor cell lines were maintained 
in RPMI-1640 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 
100 units/ml penicillin, and 100 μg/ml streptomycin (Invitrogen).  
3.2.2 Peptide Synthesis 
Peptides and lipopeptides (Table 3.1) containing an H-2Db restricted CTL epitope (amino acid 
49-57, RAHYNIVTF) derived from HPV 16 E7 protein were synthesized and purified in 
Molecular Medicine Institute Peptide Synthesis Facility in the University of Pittsburgh. Briefly, 
lipopeptides used in this study were generated by elongating the N-terminal of E7 peptide with a 
linker peptide Lys-Ser-Ser (KSS) and a palmitic acid was then attached to the alpha or epsilon 
amino group of the Lys residue. An unlipidated version of KSS-elongated E7 peptide 
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(abbreviated KSS-E7) or a palmitoylated E7 peptide (fatty acid attached to N-terminal Arg 
residue without a spacer sequence; abbreviated PA-E7) were used as controls. 
3.2.3 Preparation and characterization of DOTAP/lipopeptides  
Cell culture grade water (Cambrex, Walkersville, MD) was used in all liposome preparations. 
Lipopeptide was mixed with DOTAP in CHCl3/MeOH (1:1 mixture) followed by evaporation 
under a steady stream of dry nitrogen gas. Traces of organic solvent were removed by vacuum 
desiccation overnight. Lipopeptide/lipid films were hydrated by adding water and incubated at 
room temperature for 12 h. The suspensions were sonicated in a bath type sonicator for 10 min 
followed by extrusion (Hamilton Co., Reno, NV) through 400, 200 and 100 nm polycarbonate 
membrane (Nuclepore, Pleasanton, CA), and were stored at 4ºC before use. For preparation of 
DOTAP/E7 or DOTAP/KSS-E7, DOTAP lipid film was hydrated in an aqueous solution 
containing the water-soluble peptide.  
Peptide encapsulation efficiency was determined by the percentage of the liposome-
bound peptide using LavaPepTM peptide quantification kit (Fluorotechnics, Sydney, Australia). 
Since unincorporated lipopeptide aggregated and could not pass the exclusion filter, the 
incorporated lipopeptide was measured as the amount associated with the extruded liposomes. 
The liposomes were dissolved in 1% SDS and the amount of peptide was measured as described 
above. The data were reported as the mean ± SD (n=3). For water-soluble peptide such as native 
E7 and KSS-E7, the unbound peptide was separated from the complex by a Microcon® 
centrifugal filtration device (Millipore, Bedford, MA) [9]. The concentration of the unbound 
peptide was measured using LavaPepTM according to the manufacturer’s instructions. The 
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efficiency of encapsulation was determined as (100 - % unbound peptide) and was reported as 
the mean ± SD (n=3).  
3.2.4 Mice and immunizations 
All work performed on animals was in accordance with and approved by our institutional 
IACUC. C57BL/6 female mice of 6-7 weeks old were purchased from Charles River 
Laboratories (Wilmington, MA) and were used in all animal studies. Subcutaneous tumors were 
established by injecting TC-1 cells (105 cells) into the hair-trimmed flank of the mouse on day 0. 
Mice were treated with a liposomal formulation subcutaneously (s.c.) at the other side of flank 
on day 6 unless otherwise stated. The size of the tumor was measured using a caliper two or 
three times a week. Tumor size was determined by multiplying the two largest dimensions of the 
tumor. 
3.2.5 Analysis of in vivo CTL response 
In vivo CTL activity of E7-specific cytotoxic T cells was enumerated according to the protocol 
of Byers et al. [17] with minor modifications. In brief, spleen cells from syngenic mice were 
RBC lysed followed by pulsing with 10 μM E7 peptide or without peptide in complete medium 
for 1 h at 37°C. Both spleen cell populations were stained with equal amount of 2 μM PKH-26 
(Sigma-Aldrich) according to manufacturer’s instruction. The peptide pulsed and unpulsed 
populations were loaded with 4 and 0.4 μM CFSE (Molecular Probes), respectively, at 37°C for 
15 min. The two cell populations were mixed together (1:1) for tail vein injection to the control 
or the immunized mice (107 cells per mouse). At 16 h after injection, spleen cells from the 
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recipient mice were isolated and single cell suspension were prepared prior to flow cytometric 
analysis. The number of CFSEhigh and CFSElow population were determined and the in vivo E7 
specific lysis percentage was enumerated according to a published equation [17]. 
3.2.6 Intracellular cytokine staining  
All anti-mouse antibodies used for flow cytometric analysis were purchased from BD 
Pharmingen (San Diego, CA) or eBioscience, Inc (San Diego, CA). For the measurement of IFN-
γ producing CD8+ T cells, spleen cells were isolated from the control or the immunized mice 7-
10 days after the last immunization. 2 × 106 spleen cells were incubated with 5 μg/ml E7 peptide 
or without peptide for 6 h in the presence of 1 μl/ml of GolgiPlug (BD Pharmingen). After 
washing by FACS buffer, cells were stained directly with anti-CD8a (53-6.7) on ice for 30 min. 
Prior to staining with anti-IFN-γ mAb (XMG1.2), cells were fixed and permeabilized using the 
Cytofix/Cytoperm™ kit (BD Pharmingen) according to the manufacturer’s instruction. Cells 
were finally resuspended in 300 μl stain buffer and analyzed using a flow cytometer. 
3.2.7 MHC class I binding assay 
RMA-S cells at a concentration of 5 × 105 cells/ml were incubated overnight at 27°C with native 
E7 or KSS-E7 peptide (10 μM). Cells incubated with medium were used as a control. Cells were 
then transferred to 37°C and incubated for 2 h. After washes, cells were stained with 
fluorescently conjugated mAbs against H-2Db or H-2Kb molecules on the cell surface prior to 
flow cytometry analysis. 
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3.2.8 Statistical analysis 
Data were analyzed statistically using a two-tailed Student’s t-test. Differences in data were 
considered statistically significant when p value was less than 0.05. 
3.3 RESULTS 
3.3.1 Encapsulation efficiency of E7-lipopeptide in the cationic DOTAP liposome 
In order to improve the efficiency of the DOTAP/E7 therapeutic vaccine, one of the strategies 
was to increase the incorporation of the antigen in the liposome by utilizing lipopeptides. The 
lipopeptides used in this work are described in Table 3.1. When peptide loading was 2.5 mol% 
of the total lipid, the entrapment efficiency of E7-lipopeptides (i.e., α- or ε-PA-KSS-E7) within 
DOTAP liposome reached up to 90% compared to ~25% incorporation of the water-soluble 
native E7 and KSS-E7 peptides.  
 
Table 3.1. Composition of the synthetic lipopeptides and the peptide entrapment efficiency  
in the DOTAP liposome at molar ratio lipopeptide: DOTAP = 1:40. 
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As shown in Fig. 3.1, varying amounts of ε-PA-KSS-E7 lipopeptide (0.16 mol% to 10 
mol%) were dissolved with DOTAP lipid of 100 nmol in an organic solvent and the 
incorporation rate was measured following liposome preparation. For all lipopeptide complexes, 
the entrapment efficiency decreased with increasing lipopeptide loading. The incorporation rate 
was nearly 95% when lipopeptide concentration did not exceed 2.5 mol%. When the peptide 
loading was increased to 5 mol%, approximately 70-75% entrapment efficiency was measured. 
Furthermore, less than 60% of lipopeptide was incorporated into the liposomes when lipopeptide 
was loaded at 10 mol%. The lost lipopeptide at higher loading ratio could be mostly recovered 
from the polycarbonate membrane which was used during extrusion (data not shown). These 
results demonstrate that lipopeptides exhibit superior entrapment efficiency compared to the 
native E7 peptide. However, the incorporation rate decreases with the increasing loading of 
lipopeptide; it exceeded the solubility limit at the high loading ratios. 
 
Figure 3.1. The entrapment efficiency of the E7-lipopeptide in DOTAP liposome.  
Lipopeptide varying from 0.16 to 10 nmols was mixed with DOTAP lipid of 100 nmol and the peptide entrapment 
efficiency was measured after liposome preparation. The solid line shows a regression curve w/ a slope equal to 95%. 
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3.3.2 Anti-tumor activity was enhanced by incorporation of E7-lipopeptide in the DOTAP 
liposome 
Previous studies in our group have shown that a MHC class I peptide epitope derived from HPV 
(type 16) E7 protein encapsulated in cationic DOTAP liposomes can generate a therapeutic 
effect against the HPV16 E7 positive tumor cell line, TC-1 [9, 10]. To test whether the anti-
tumor activity is enhanced by use of the lipopeptide, a series of E7-lipopeptides (Table 3.1) were 
synthesized and formulated in the DOTAP liposomes as described.  
As shown in Fig. 3.2, TC-1 tumor bearing mice were given a single-dose treatment on 
day 6 with DOTAP/E7 (containing 10 nmol or 5 nmol peptide) or DOTAP/E7-lipopeptide 
formulations containing 5 nmol of the antigen. DOTAP/E7 with 5 nmol of peptide (suboptimal 
dose) did not show a significant anti-tumor activity. On the contrary, both of the E7-lipopeptides 
(α- or ε-PA-KSS-E7) at 5 nmol of antigen, when formulated in DOTAP liposome, showed a 
significantly enhanced therapeutic effect (**p < 0.01) compared to the native E7 of 5 nmol. The 
anti-tumor activity elicited by the lipopeptides was similar to that of DOTAP/E7 at 10 nmol (i.e. 
optimal peptide dose). DOTAP liposome alone did not show anti-tumor activity. PA-E7, which 
is a palmitoylated E7 peptide (without the KSS spacer), when formulated in DOTAP liposome 
failed to show an enhanced anti-tumor activity as seen in other lipopeptide formulations, likely 
owing to the epitope being hidden by directly attaching a fatty acid to the peptide. In addition, an 
unlipidated version of KSS-elongated E7 peptide (KSS-E7) exhibited a larger effect (*p < 0.05) 
in tumor suppression than the native E7. Under these conditions, E7-lipopeptides formulated in 
DOTAP liposome showed an enhanced anti-tumor activity compared to the original DOTAP/E7 
formulation.  
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 Figure 3.2. Anti TC-1 tumor activity was enhanced by incorporation of E7-lipopeptide in the cationic 
liposomal formulation.  
TC-1 tumor bearing mice (8-12 mice per group) received a single treatment on day 6 with DOTAP/E7 (containing 
E7 peptide of 5 or 10 nmols) or DOTAP/E7-lipopeptide (containing 5 nmol peptide) or DOTAP lipid alone. Mice 
treated with dextrose (5 %) were used as a negative control. Tumor size was determined by multiplying the two 
largest dimensions of the solid tumor. The mean of tumor sizes of each group at day 24 was compared to that of the 
group which was received DOTAP/E7 (5 nmol) and was analyzed by Student’s t-test (* p< 0.05, ** p< 0.01). 
 
3.3.3 In vivo cytotoxic T-lymphocytes were elicited by DOTAP/E7-lipopeptide 
formulation 
It is important to evaluate whether a candidate cancer vaccine would be suitable for inducing a 
primary cytotoxic T-lymphocyte (CTL) response since CTLs are essential for eradicating tumor 
growth and preventing cancer recurrences [18, 19]. To avoid the possible overestimation of CTL 
function due to in vitro restimulation and expansion process, we evaluated CTL induced in vivo 
by DOTAP/E7 or DOTAP/E7-lipopeptide vaccine (Fig. 3.3a).  
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 Figure 3.3. Immunization w/ DOTAP/E7-lipopeptide formulation elicited an enhanced in vivo CTL response. 
A, C57BL/6 mice were s.c. immunized with DOTAP/E7 (containing E7 peptide of 5 or 10 nmols), DOTAP/KSS-E7 
(5 nmol), DOTAP/E7-lipopeptide (5 nmol) or DOTAP lipid alone at day 0 and day 10. Mice left untreated were 
used as a negative control. Seven days after the last immunization, representative mice were i.v. injected with an 
equivalent amount of E7-pulsed (labeled with 4 μM CFSE) and non-pulse (labeled with 0.4 μM CFSE) spleen cells 
obtained from a syngenic donor. 16 h later, spleen cells from the adoptively transferred mice were harvested and the 
proportions of the CFSEhigh and CFSElow cells were analyzed by flow cytometry. B, Percentage of specific anti-E7 
killing was shown. The mean of the percentage from each group was compared to that of the group received 
DOTAP/E7 (5 nmol) and was statistically analyzed by t-test (** p < 0.01, n = 4). 
 
As described in Materials and Methods, a mixture containing equal amounts of E7-pulsed 
CFSEhigh and unpulsed CFSElow spleen cells from a syngenic donor was i.v. injected into mice at 
7 days after the last immunization. The specific lysis of E7-pulsed cells was analyzed by flow 
cytometry at 16 h after the adoptive transfer. The mice immunized with DOTAP/E7 antigen (10 
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nmol) could generate a superior E7-specific killing compared to those immunized with lower 
amounts of antigen DOTAP/E7 (5 nmol). In contrast to the native E7 formulation, mice 
receiving 5 nmol α- and ε-PA-KSS-E7 but not PA-E7 formulated in DOTAP liposome 
efficiently eliminated about 80% of E7-pulsed targets (Fig. 3.3b). In addition, the mice receiving 
DOTAP/KSS-E7, were also capable of killing 60% of in vivo targets while the mice receiving 
DOTAP alone did not generate a noticeable E7-specific CTL response. The results suggested 
that E7-lipopeptides formulated in DOTAP liposome elicited an improved in vivo CTL response 
in than the native E7 peptide. 
3.3.4 IFN-γ production from functional CD8+ T cells was induced by DOTAP/E7-
lipopeptide 
To assess the epitope-specific immune response induced by DOTAP/E7-lipopeptide vaccination, 
IFN-γ producing CD8+ T cells were analyzed (Fig. 3.4). Spleen cells from control or immunized 
mice were isolated at one week after the final immunization. After stimulation with 5 μg/ml E7 
peptide (Fig. 3.4a, lower) or without peptide (Fig. 3.4a, upper), intracellular staining for IFN-γ 
was performed. The numbers shown in the dot plots represent the percentage of CD8 and IFN-γ 
double positive cells within the CD8+ population. As depicted in Fig. 3.4b, the numbers of IFN-γ 
producing CD8+ cells were significantly higher in mice that received 5 nmol of ε-PA-KSS-E7 
formulated in the DOTAP liposomes than those of both 10 and 5 nmols of the native E7 
formulation (**p < 0.01). Again, KSS-E7 showed a superior result compared to the native E7 at 
the equal antigen amount. The IFN-γ production by the CD8+ cells was in an E7-specific manner, 
as the unpulsed cells showed only background level of the cytokine. These results show that 
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incorporation of α- or ε-PA-KSS-E7 lipopeptides into DOTAP liposomes clearly enhanced the 
amount of IFN-γ producing CD8+ T lymphocytes in the lymphoid organ. 
 
 
Figure 3.4. Immunization w/ DOTAP/E7-lipopeptide increased the production of IFN-γ secreting CD8+ T cells. 
A, Mice were immunized as described and seven days after the last immunization, spleen cells from immunized 
mice were isolated. The cells were stimulated in vitro with or without E7 peptide (5 μg/ml) for 6 h, and were stained 
with a surface CD8 marker and an intracellular IFN-γ cytokine prior to FACS analysis. The numbers shown on 
contour plots represent the percentages of CD8+IFN-γ+ T cells gated on the total CD8+ cells. Representative figures 
in four experiments performed. B, The percentage of CD8+IFN-γ+ double positive cells per 104 total CD8+ from each 
treatment group were shown as mean ± SD and were statistically analyzed by paired t-test (** p < 0.01, n = 4). 
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3.3.5 H-2Db was up-regulated by KSS-E7 using RMA-S binding assay 
Both native E7 and KSS-E7 are water-soluble peptides that reach similar entrapment efficiency 
in liposome. KSS-E7 appears to have a better immunogenicity compare to the native E7. To 
elucidate the mechanism by which KSS-E7 peptide exhibited superior antigen activity than the 
native E7, the binding of MHC class I molecules by E7 and KSS-E7 peptide was investigated. 
E7 peptide (a.a. 49-57) is a known epitope restricted to H-2Db [20] and it up-regulated more than 
4-fold of H-2Db molecules on RMA-S cells compared to the control (Fig. 3.5). Intriguingly, an 
8-fold increase in the mean fluorescence was observed for KSS-E7 peptide. No up-regulation of 
H-2Kb molecules was detected on RMA-S cells after incubating with either E7 or KSS-E7 
peptide. The results suggest that KSS-E7 has an improved binding affinity for H-2Db molecules 
than native E7 peptide, which may lead to an overall superior anti-tumor activity when 
formulated in the DOTAP liposomes.  
 
Figure 3.5. MHC class I molecules up-regulation by E7 and KSS-E7 peptide.  
RMA-S cells were incubated with E7 or KSS-E7 peptide at 10 μM and the up-regulation of MHC class I molecules 
was detected by a fluorescently conjugated mAb against H-2Db or H-2Kb. Cells treated with medium were used as a 
control. The results are expressed as mean fluorescence intensity of triplicate determination ± SD and were 
statistically analyzed by paired t-test (** p < 0.01, n = 3) 
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3.3.6 Potent anti-tumor activity was induced by DOTAP/E7-lipopeptide vaccine 
To further study the potency of the DOTAP/E7-lipopeptide vaccine against the existing tumor, 
the varied doses of ε-PA-KSS-E7 (i.e. 1.25 to 10 nmols per injection) were investigated (Fig. 
3.6a). The tumor bearing mice that received one single treatment of DOTAP/ε-PA-KSS-E7 with 
5 or 10 nmol of antigen could induce full tumor growth inhibition (** p < 0.01) compared to the 
partial tumor growth inhibition in those injected with DOTAP/E7 (5 nmol). The formulation still 
showed a partial anti-tumor effect (* p < 0.05) when the lipopeptide amount was decreased to as 
low as 1.25 nmol.  
To evaluate whether the improved vaccine could also be effective in the treatment of TC-
1 tumor of larger sizes, the treatment was delayed until day 10 instead of day 6 (Fig. 3.6b). 
Whereas both DOTAP/E7 (10 nmol) and DOTAP/ε-PA-KSS-E7 (5 nmol) vaccines given on day 
6 showed an effective anti-tumor activity, mice receiving the lipopeptide formulation on day 10 
exhibited a superior effect on tumor inhibition than the native E7 peptide given at the same day 
(* p < 0.05). Overall, the DOTAP/E7-lipopeptide vaccine described in this work was capable of 
generating efficient anti-tumor activity even at the low antigen dose compared to the original 
DOTAP/E7 formulation. Moreover, the improved vaccine activity was also demonstrated growth 
inhibition of larger tumors. 
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 Figure 3.6. The potency of DOTAP/E7-lipopeptide vaccine for the treatment of TC-1 tumor.  
A, TC-1 Tumor bearing mice were established as described and were given a single treatment of DOTAP/E7 or 
DOTAP/ε-PA-KSS-E7 formulation on day 6.Lipopeptide varying from 1.25 to 10 nmols per dose were investigated. 
The mean of the tumor sizes from each group at day 24 was compared to that of the group received DOTAP/E7 (5 
nmol) and was analyzed by Student’s t-test (* p< 0.05, ** p< 0.01, n = 6). B, Tumor bearing mice were treated with 
DOTAP/E7 (10 nmol) or DOTAP/ε-PA-KSS-E7 (5 nmol) formulation on day 6 (solid symbols) or day 10 (open 
symbols). The mean of the tumor sizes at day 32 was compared between the two formulations (* p< 0.05, n = 6). 
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3.4 DISCUSSION 
Development of safe and effective therapeutic cancer vaccines for human use remains an urgent 
and unmet medical need. In this report, we demonstrate an improved liposomal lipopeptide 
vaccine for the treatment of HPV positive tumors. By linking to a mono-palmitic acid to KSS-
elongated E7 peptide (at either α or ε position), the peptide encapsulation efficiency within 
liposomes was higher than that of the unmodified E7 peptide. The DOTAP/E7-lipopeptide 
vaccine induced an overall enhancement in generating antigen-specific CTL for eradicating HPV 
positive TC-1 cells (Fig. 3.3). When given at a reduced amount (5 nmol or less) of peptide dose 
to the tumor bearing mice, DOTAP/E7-lipopeptide exhibited a superior anti-tumor activity 
compared to the original DOTAP/E7 formulation at a full dose (10 nmol) (Fig. 3.2 and 3.6a). 
Furthermore, the therapeutic effect of DOTAP/E7-lipopeptide was also effective for suppression 
of tumor growth in later stages of tumor progression, suggesting applications in progressed 
cancer treatments (Fig. 3.6b). 
The enhanced antigenicity and anti-tumor activity of the lipopeptide were correlated with 
the enhanced encapsulation of the lipopeptide in the liposomes. As shown in Table 3.1, the 
entrapment efficiency of lipopeptide reached to 90% when the peptide loading is 2.5 mol% 
among total lipid, whereas the native water soluble E7 peptide only incorporated into the 
liposome at about 25%. Similar enhanced liposome encapsulation of lipopeptides has also been 
reported [21-23]. In order for the peptide to be presented by the MHC class I pathway, the 
peptide has to enter the cytoplasm of the APC. Cationic liposomes deliver the encapsulated, but 
not free, peptide into the APCs, allowing the peptide to be released and later presented in the 
MHC class I pathway. Thus, the significantly higher the encapsulation of the peptide would 
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allow for increased peptide delivery and therefore, higher antigenicity, can be expected. 
However, there is an exception to the rule. 
Our data indicates that the lipopeptide PA-E7 without the spacer sequence Lys-Ser-Ser, 
achieved high degree of liposome encapsulation, but did not show an enhanced anti-tumor 
activity compared to those with the spacer amino acids. The phenomenon was likely a result of 
some structural constraints where the conjugated fatty acid may cover the CTL epitope, thereby 
minimizing its recognition. Verheul et al. have also shown that the amino acid spacer sequences 
influence the immunological properties of the lipopeptide conjugates [24]. In addition to enter 
the endosomal pathway as exogenous soluble protein and peptides, lipopeptides must be 
processed to be free peptide again once entering into the cytoplasm of the APC. By adding a 
linker sequences, it may prevent the CTL epitope from being altered during the processing of the 
lipopeptide in the cytosol. Several additional spacer amino acids have been investigated thus far 
including CSS and CSKKK [25, 26] and they showed a stronger immunogenicity than those 
without a spacer sequence.  
The KSS-E7 peptide formulated in DOTAP appears to be a better vaccine formulation 
than the native E7 peptide as demonstrated by the tumor growth inhibition and increased 
antigencity, although their liposome encapsulation efficiencies were comparable. Interestingly, 
we found that mice receiving DOTAP/KSS-E7 generated an increased functional CTL response 
(Fig. 3.3 and 3.4) as well as an enhanced anti-tumor activity (Fig. 3.2) compared with the native 
E7. It is known that the capacity of a peptide to bind and stabilize MHC class I molecules is 
directly correlated with its ability to induce specific CTL responses [20] [27]. Our results 
tempted us to study the MHC class I binding affinity of the native and the KSS-elongated E7 
peptides. RMA-S cell line was originally selected from mutated cells on the basis of low cell 
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surface expression of MHC class I molecules and inability to present endogenous antigens. The 
synthesis of class I molecule heavy and light chains is normal, however the mutant cells 
undergoes various protein degradation routes at 37ºC, resulting in a decreased number of MHC 
on the surface of RMA-S cells. At 27ºC, the breakdown of MHC molecules is slow and H-2Db or 
Kb molecules are able to appear on the cell surface at the reduced temperature [28]. The labile 
class I molecules at 37ºC can be stabilized by exposing cells to peptides which interact with H-
2Db or Kb. Although the detailed mechanism is not known, our results shown in Fig. 3.5 
indicated that KSS-E7 bound with a higher affinity with H-2Db, but not Kb molecules than the 
native E7 peptide. Thus, it is possible that the enhanced antigenicity of α and ε-PA-KSS-E7 
lipopeptides was due to both an enhanced liposome encapsulation and an elevated biding affinity 
with the H-2Db molecule for antigen presentation. 
In summary, the results from this report demonstrate that the improved formulation, 
DOTAP/E7-lipopeptide is a potential therapeutic vaccine for the treatment of HPV positive 
tumors. The vaccine described here maintains the benefits of simplicity and safety from its 
original version, DOTAP/E7, which contains only two molecules, and the lipopeptide 
formulation further improves the vaccine by reducing the amount of antigen required to suppress 
progression of the cancer and tumor growth. Most importantly, the DOTAP/E7-lipopeptide 
vaccine induced an overall increased CTL activity that is essential for the enhanced tumor 
clearance and reduced rates of tumor recurrence. This novel formulation represents an excellent 
candidate for future cancer vaccine development.  
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4.0  INDUCTION OF HLA-A2 RESTRICTED T CELL PROLIFERATION 
AND TUMOR-SPECIFIC CYTOTOXIC T LYMPHOCYTE RESPONSES BY 
A LIPOSOMAL PEPTIDE FORMULATION 
Human papillomavirus (HPV) oncoproteins E6 and E7, which are constitutively expressed in the 
cervical carcinoma cells, are ideal targets for developing immunotherapies for treatment of 
existing cervical cancer. Induction of cytotoxic T lymphocytes (CTL) requires interaction with 
activated antigen-presenting dendritic cells (DC) which play a central role in eradicating virus 
infected cells and malignant tumors. In the current study, we have developed a peptide-based 
therapeutic cancer vaccine, DOTAP/hE7, which consists of a cationic lipid and a HLA-A2 
restricted CTL peptide epitope derived from E7 protein. Our data demonstrated that the 
DOTAP/hE7 vaccine effectively activated human DC. In vitro stimulation of naïve HLA-A2+ 
human T lymphocytes by DOTAP/hE7-activated autologous DC elicited a stronger clonal T cell 
proliferation and higher HPV-specific CTL responses than those stimulated with DC which had 
been treated with the peptide alone. Interestingly, DOTAP induced ERK1/2 phosphorylation in T 
cells, also resulted in T cell proliferation. In addition, T cells stimulated with DOTAP/E711-20 
exhibited antigen specific CTL capability. In vivo CTL and anti-tumor activity induced by 
DOTAP/hE7 vaccine was also demonstrated in an HLA-A2 transgenic mouse model. Overall, 
the data suggested that DOTAP/hE7 has the potential to be a therapeutic cervical cancer vaccine 
and should be useful in clinical applications for the treatment of HPV-related neoplasia. 
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4.1 INTRODUCTION 
The incidence of cervical cancer is highly associated with the infection of human papillomavirus 
(HPV), particularly the subtype HPV 16. Strategies to develop clinical applicable vaccines with 
prophylactic or therapeutic effect have been extensively studied. Although a preventative vaccine 
against HPV infection has already been launched in the market [1] [2], it cannot treat the existing 
HPV-associated malignant lesions [3]. Treatment options for cervical neoplasia are limited to 
cryotherapy, radiation therapy and chemotherapy [4]. Thus, development of a safe and effective 
therapeutic vaccine for treatment of cervical cancer remains an urgent and unmet need.  
Since HPV E6 and E7 oncoproteins are consistently retained and expressed in cervical 
cancer cells, they are good targets for developing novel immunotherapies [5]. Many investigators 
have shown that induction of MHC class I restricted cytotoxic T lymphocytes (CTL) against 
HPV E6 or E7 play a central role in eradicating virus infected cells and malignant tumors [6]. 
These approaches have led to the development of several experimental therapeutic vaccines for 
the treatment of the cancer, including protein or peptide-based vaccines [7] [8] and DNA 
vaccines [9] [10]. HPV-specific CTL activity was induced in a murine model system upon 
receiving the vaccine. Some of these vaccines have already launched to various stages of clinical 
trials [11] [12]. 
Instead of the injectable vaccines, alternative strategies include adoptively transferring 
autologous E6 or E7 specific CTL to the host. Thus, patients essentially receive their own cells 
but not the vaccine which may cause toxicity. Studies from different groups have demonstrated 
that human CTL against HPV can be established by in vitro restimulation of peripheral blood 
mononuclear cells (PBMC) obtained from cervical cancer patients. Indeed, various stimulation 
methods using peptides [13], proteins [14], and vaccinia virus [15] have shown the ability of 
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inducing of primary HPV-specific CTL. No matter which method was used, HPV-specific CTL 
could not be detected in the PBMCs from normal donors unless DC was used as antigen-
presenting cells in vitro [16] [17].  
Previous studies from our lab have led to the development of a therapeutic cancer vaccine 
formulation consists of only a cationic lipid DOTAP and a peptide antigen derived from HPV 16 
E7 oncoprotein [18]. Upon DOTAP stimulation, murine bone marrow derived dendritic cells 
(BMDC) were activated for the expression of the co-stimulatory molecules, CD80 and CD86 
[19]. The activation of ERK pathway and several chemokines such as CCL2 were also observed 
in DOTAP-activated BMDC [20]. Animal studies suggested that DOTAP liposome alone 
provides both an antigen carrier and a potent adjuvant activity in inducing migration of the 
activated DC to the draining lymph node (DLN), thereby leading to the generation of in vivo 
antigen-specific CD8+ T lymphocyte against antigen-bearing tumor cells [18].  
These results prompted us to take advantages of the fact that DOTAP liposome functions 
as a strong DC stimulator to investigate and confirm the potency of DOTAP/E7 vaccine in 
human. Herein, we compared the immunogenicity of two HLA-A2 restricted CTL peptide 
epitopes (E711-20 and E786-93) which were encapsulated in DOTAP liposome. We demonstrate the 
enhanced induction of the HLA-A2 restricted HPV-specific CTL in normal human PBMC by in 
vitro stimulation using DOTAP/hE7-activated autologous DC or DOTAP/hE7 alone. The in vivo 
anti-tumor activity of DOTAP/hE7 vaccine was also confirmed using an HLA-A2 transgenic 
mice model. 
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4.2 MATERIALS AND METHODS 
4.2.1 Lipids, reagents and cell lines 
DOTAP was purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Phorbol 12-myristate 13-
acetate (PMA), ionomycin and lipopolysaccharide (LPS) were purchased from Sigma-Aldrich 
(St. Louis, MO). KG-1, a human myelogenous leukemia cell line, and CaSki, a human cervical 
carcinoma, were obtained from the Lineberger Comprehensive Cancer Center at the University 
of North Carolina at Chapel Hill. T2 cells which express only the HLA-A*0201 allele were used 
as target cells in CTL assay. TC-1/A2 cell line was generated by transducing TC-1, which is an 
established E7-expressing cell line, with a retrovirus encoding the HLA-A2 molecule [21]. Both 
of T2 and TC-1/A2 cells were kindly provided by Dr. T.C. Wu at Johns Hopkins University 
(Baltimore, MD). All of above tumor cell lines were maintained in RPMI-1640 medium 
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 
and 100 μg/ml streptomycin (Invitrogen).  
4.2.2 Generation of human DC 
Human DC were prepared according to the protocol by Dees et al [22]. In brief, buffy coats from 
healthy donors were purchased from the American Red Cross (Durham, NC) and the PBMCs 
were separated by centrifugation on a ficoll hypaque gradient. After washing by PBS, cells were 
suspended in medium and allowed to adhere to the plastic dishes for 2 h. Non-adherent PBMCs 
were then removed from the flask. The adherent mononuclear cells were cultured with AIM-V 
(Invitrogen) culture media supplemented with 10% human AB serum and human recombinant 
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cytokines GM-CSF (800 units/ml) and IL-4 (500 units/ml) (R&D system, Minneapolis, MN). 
Fresh medium with cytokines were replenished to the culture every 48-72 h. On day 7, immature 
DC were harvested and used for phenotype analysis and antigen presentation. 
4.2.3 Peptide Synthesis 
The human E711-20 and E786-93 peptides containing an HLA-A2 restricted CTL epitope (Table 4.1) 
derived from HPV 16 E7 protein were synthesized and purified with a purity greater than 95% in 
Molecular Medicine Institute Peptide Synthesis Facility at the University of Pittsburgh. 
Ovalbumin (OVA) peptide (SIINFEKL) was a gift kindly provided by Dr. M.J. Cho at 
University of North Carolina at Chapel Hill. 
4.2.4 Preparation and characterization of DOTAP/hE7  
Cell culture grade water (Cambrex, Walkersville, MD) was used in all liposome preparations. 
Briefly, lipid films were made in a glass vial by evaporating the chloroform solution under a 
steady stream of dry nitrogen gas. Traces of organic solvent were removed by vacuum 
desiccation overnight. Lipid films were hydrated for 12 h by adding required amount of water 
containing E7 peptide. The suspension was sonicated in a bath type sonicator for 5 min followed 
by extrusion (Hamilton Co., Reno, NV) through a 100 nm membrane filter (Nuclepore, 
Pleasanton, CA). DOTAP/hE7 formulations were stored at 4ºC before use.  
The particle size and the zeta (ζ) potential of the liposomal complexes were measured 
following the manufacturer’s instruction using a Coulter N4 Plus particle sizer (Beckman Coulter, 
San Francisco, CA) and a ZetaPlus (Brookhaven Instruments, Corp., Holtsville, NY), 
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respectively. Peptide encapsulation was determined by the percentage of liposome-bound peptide 
using a previously published method [18]. The data are reported as the mean ± SD (n=3). 
4.2.5 Antibodies and flow cytometry analysis 
All anti-human antibodies used for flow cytometric analysis were purchased from BD 
Pharmingen (San Diego, CA). KG-1 cells or primary DC suspensions were incubated with 
fluorescently conjugated antibodies to surface antigens for 30 min at 4˚C. The following Abs 
were used: anti-CD11c (B-ly6), anti-CD80 (L307.4), anti-CD83 (HB-15e), anti-CD86 (2331) 
and anti-HLA-DR (L243). Isotype control Abs were used to set the background for the surface 
Ab labels. After washing with PBS, cells were resuspended in 300 μl stain buffer and analyzed 
using a BD FACSCanto digital flow cytometer (San Diego, CA). 
4.2.6 In vitro induction of human primary CTL response 
On day 7, immature DC were harvested and pulsed with hE7 peptide (40 μM) or DOTAP/hE7 
(containing 50 μM lipid and 40 μM peptide) in the presence of β2-microglobulin (3 μg/ml) in the 
culture media for 4 h at 37°C. After washing by PBS twice, cells were treated with mitomycin-C 
at 25 μg/ml for 20 min. DC were then washed at least three times with PBS prior to mixing with 
lymphocytes. HLA-A2+ human lymphocytes were obtained from the non-adherent PBMC after 
two consecutive plastic adherence procedures. On day 0, lymphocytes were cultured in a 24-well 
plate with autologous DC (10:1 ratio) which had been pulsed with E7 peptide or DOTAP/E7. 
The lymphocyte culture media contained AIM-V medium supplemented with 10% human serum 
and cytokine IL-7 (20 units/ml). An additional 1-mL of fresh culture medium with IL-2 (20 
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units/ml) was added to each well on day 2. The lymphocytes were washed and re-stimulated with 
E7 pulsed or DOTAP/E7-pulsed DC on day 7 and day 14 with the same preparation procedure. 
For induction of CTL in the absence of DC, lymphocytes were incubated with DOTAP/hE7 
(containing 10 μM hE7) in the culture medium. Three days after the third stimulation, images of 
the lymphocyte cultures were taken using a Nikon phase contrast microscope. The IFN-γ level in 
the culture supernatant was measured by BD ELISA Set (BD Pharmingen) according to 
manufacturer’s instruction. 
Seven days after the last restimulation, T lymphocytes were harvested and used as 
effectors in CTL assay. In brief, T2 or CaSki target cells were labeled with PKH-67 (Sigma-
Aldrich) according to manufacturer’s instruction. The mixture of effectors and labeled targets 
were plated into a 96-well U-bottom plate at various effector:target (E:T) ratios and the cell lysis 
reactions were carried out for 4 h at 37°C. The cells were then harvested and stained with 
propidium iodide (Sigma Aldrich) prior to flow cytometric analysis. The percentage of E7-
specific lysis was determined by the proportion of PI positive cells within the FL1 (PKH-67) 
positive region. 
4.2.7 Western blot analysis 
Human lymphocytes (2 × 106 cells/ml) were treated with DOTAP at 50 μM in the complete 
medium and the cell lysate was collected at different time points after treatment. Equal amount 
of total cellular protein (50 μg) was resolved on polyacrylamide/SDS gels (Bio-Rad, Hercules, 
CA) and then transferred to a polyvinylidene difluoride membrane. The membrane was blocked 
with 5% non-fat milk in PBS for 1 h and incubated overnight with primary Ab at 4°C. After 
 90 
washing with PBS three times, the membrane was incubated with horseradish peroxidase (HRP) 
conjugated secondary Ab for 1 h. The enzyme activity associated with the protein bands was 
detected using ECL PlusTM (Amersham, Pittsburgh, PA) followed by autoradiography.  
4.2.8 Mice and immunizations 
All work performed on animals was in accordance with and approved by the institutional IACUC. 
Five to six week old HLA-A*0201 transgenic mice were purchased from the Jackson Laboratory 
(Bar Harbor, ME). Subcutaneous tumors were established by injecting TC-1/A2 cells (106 cells) 
into the hair-trimmed flank of the mouse on day 0. Mice were treated with a DOTAP/hE7 
formulation subcutaneously (s.c.) at the other side of flank on day 6. The size of the tumor was 
measured using a caliper two or three times a week. Tumor size was determined by multiplying 
the two largest dimensions of the tumor. 
4.2.9 Analysis of in vivo CTL response 
Mice were immunized twice with DOTAP/hE7 with one week interval between each dose. In 
vivo CTL response was assessed 7 days after the last immunization. Spleen cells from syngenic 
mice were RBC lysed followed by pulsing with 10 μM E711-20, E786-93 or without peptide in 
complete medium for 1 h at 37°C. Three spleen cell populations were stained with equal 
amounts of 2 μM PKH-26 (Sigma-Aldrich) according to manufacturer’s instruction. The E711-20-
pulsed, E786-93-pulsed and the unpulsed populations were then loaded with 5, 0.5 and 0.05 μM 
CFSE (Molecular Probe), respectively, at 37°C for 15 min. The three populations were mixed 
together (1:1:1) for tail vein injection to the control or the immunized mice (107 cells per mouse). 
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At 16 h after injection, spleen cells from the recipient mice were isolated and single cell 
suspension were prepared prior to flow cytometric analysis. The numbers of CFSEhigh, 
CFSEmedium and CFSElow population were determined and the in vivo E7 specific lysis percentage 
was enumerated according to a published equation [23]. 
4.2.10 Statistical analysis 
Data were analyzed statistically using a two-tailed Student t-test. Difference in data was 
considered statistically significant when p value was less than 0.05. 
4.3 RESULTS 
4.3.1 Characterization of DOTAP/hE7 complexes 
DOTAP/hE7 formulations used in this study consisted of a cationic lipid DOTAP and a peptide 
antigen containing an HLA-A2 restricted CTL epitope derived from the E7 protein of HPV 16. 
In Table 4.1, the particle size and zeta potential of the DOTAP/hE7 complexes were similar to 
those of DOTAP liposome alone. The peptide entrapment efficiency in the liposome was also 
compared between two HLA-A2 restricted peptides. E711-20 showed a significantly higher 
incorporation in the liposome than E786-93, likely owing to the stronger association between the 
more negatively charged peptide (E711-20) and the cationic liposome as compared to the less 
charged peptide (E786-93). 
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Table 4.1. Physicochemical properties and peptide entrapment 
efficiency of DOTAP/hE7 complexes 
 
 Peptide seq. Particle size (nm) 
Zeta potential 
(mV) 
Entrapment 
efficiency (%) 
DOTAP liposome - 109.8 ± 33.4 51.2 ± 4.0 - 
DOTAP/E711-20 YMLDLQPETT 125.3 ± 40.1 50.1 ± 3.5 63.6 ± 5.9 
DOTAP/E786-93 TLGIVCPI 124.8 ± 32.5 49.3 ± 4.2 17.1 ± 5.4 
n = 3 per group     
 
 
4.3.2 Activation of human DC by DOTAP/hE7 formulation 
Since the activated DC initiate the DC-T cell interactions by presenting MHC bound peptide 
antigen to T cells [24], it is important to assess whether a peptide vaccine could interact with DC 
and lead DC to activation. We first tested our DOTAP/hE7 formulation for activation of KG-1, 
which is a human myelogenous leukemia cell line. KG-1 cells have been established to possess 
the capacity to mature into both macrophages and dendritic-like cells [25] and they have been 
used to examine the processes involved in dendritic cell precursor maturation [26]. As shown in 
Fig. 4.1a, upon treatment with PMA and ionomycin, conditions which induce differentiation of 
CD34+ hematopoetic progenitor cells into dendritic cells [27], KG-1 cells expressed the DC 
lineage markers, CD11c and CD83, as well as the co-stimulatory molecules such as CD80 and 
CD86, compared to the untreated control. In addition, KG-1 cells stimulated with DOTAP/E711-
20 exhibited a similar extent of differentiation as those induced by phorbol ester. 
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Figure 4.1. Activation of human dendritic cells by DOTAP/hE7. 
A, KG-1, human DC-like cells were cultured in medium alone, PMA (10 ng/ml) plus ionomycin (100 ng/ml) for 4 
days or DOTAP/E711-20 (containing lipid 50 μM) for 1 day. Cells were harvested and stained for surface antigens 
prior to the flow cytometric analysis. Ag-specific staining is shown in grey area and the isotype matched control is 
indicated by the open area. The numbers shown on the histograms represent the mean fluorescence intensity of the 
indicated antigen. B, Primary human immature DC were prepared as described. On day 7, DC were treated with 
medium alone, LPS (200 ng/mL), DOTAP/E711-20 (containing lipid 50 μM) for 16 h and analyzed by flow cytometry. 
The numbers indicate the relative percentage of the positive populations. 
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We further investigated the effect of DOTAP on the activation of human primary DC 
(Fig. 4.1b). After in vitro culture with GM-CSF and IL-4 for 7 days, human immature DC with 
CD11c+ phenotype were treated with LPS or DOTAP/E7 for 16 h prior to FACS analysis for the 
activation markers on the cell surface. Human primary DC could be activated by both LPS and 
the DOTAP/E7 formulation, which led to the further maturation of DC toward the up-regulation 
of surface markers such as CD80, CD86 and CD83. Similar results were obtained in three 
different batches of human DC preparation. 
4.3.3 Induction of human T cell proliferation by DOTAP/hE7-pulsed DC 
Successful eradication of cancerous or infected cells in vivo by induction of cell-based immunity 
requires not only antigen delivery and activation of dendritic cells, but concomitant presentation 
of antigen to T-cells, and subsequent clonal expansion of antigen-specific cytotoxic T cell 
responses. To assess whether DOTAP/hE7 is capable of promoting antigen specific T-cell 
expansion, isolated HLA-A2+ lymphocytes (after depletion of plastic-adhered monocytes) were 
treated with autologous DC which had been pulsed with E7 peptide alone or DOTAP/hE7 
formulation followed by mitomycin-C treatment. The stimulation was repeated at least three 
times with a 7-day interval. As shown in Fig. 4.2b, lymphocytes treated with unpulsed DC 
exhibited a minimal proliferation in the culture compared to the medium control (Fig. 4.2a) 
while lymphocytes treated with peptide-pulsed DC (Fig. 4.2c and 4.2e) displayed few or 
moderate colonies of expanding T-cells. Interestingly, a strong T cell proliferation was observed 
after stimulation with DC which had been activated by DOTAP/E711-20 or DOTAP/E786-93 (Fig. 
4.2d and 4.2f). 
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Figure 4.2. Induction of Ag-specific T cell proliferation by incubating lymphocytes w/ DOTAP/E7-pulsed DC. 
Human T lymphocytes obtained from the HLA-A2 healthy donor were incubated with A, medium only; B, unpulsed 
autologous DC; C, E711-20 pulsed DC; D, DOTAP/E711-20 pulsed DC; E, E786-93 pulsed DC and F, DOTAP/E786-93 
pulsed DC. Three days after the third stimulation, the images of the culture were taken by a phase contrast 
microscope. G, IFN-γ secretion in the culture was measured by ELISA (n = 3, *P < 0.05) 
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Further confirmation of the antigen specificity for the expanding T cells was provided by 
IFN-γ secretion in the culture (Fig. 4.2g). Lymphocytes incubated with DOTAP/E711-20 or 
DOTAP/E786-93 pulsed DC showed a significant increase in IFN-γ production compared to those 
incubated with unpulsed or peptide-pulsed DC. The results indicated that the interaction between 
DOTAP/E7-activated DC and autologous lymphocytes underwent extensive expansion of T-cell 
colonies in the culture. 
4.3.4 In vitro induction of tumor-specific human primary CTL by DOTAP/E7-activated 
autologous DC 
The clonally expanded T lymphocytes induced with DOTAP/E7-activated DC were tested for 
antigen-specific cytotoxicity using a flow cytometry based method. Lymphocytes were 
stimulated with DC which had been pulsed with E711-20, DOTAP/E711-20 (Fig. 4.3a) or with E786-
93, DOTAP/E786-93 (Fig. 4.3b). Seven days after the last stimulation, CTL assay was performed 
by mixing T cell populations with the fluorescently labeled target cells. Both of the E711-20-CTL 
and E786-93-CTL showed effective killing of HLA-A2+, HPV 16+ CaSki cells (closed symbols) 
but not HLA-A2+, HPV 16- T2 cells (open symbols). More importantly, the human T cells 
stimulated with the DOTAP/hE711-20-activated DC exhibited a stronger antigen-specific CTL 
effect than those incubated with E711-20 peptide pulsed DC (P < 0.01), thereby confirming that 
the clonal expanded T cells by the DOTAP/E7-activated DC were functional, antigen-specific 
CTL. 
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Figure 4.3. In vitro induction of HPV-specific cytotoxicity of human E711-20 (A) and E786-93 (B) CTLs. 
Cytotoxicity was tested 1 week after the third stimulation of HLA-A2+ T lymphocytes with E711-20 pulsed DC (▲); 
DOTAP/E711-20 pulsed DC (●); E786-93 pulsed DC (▼); DOTAP/E786-93 pulsed DC (■) and unpulsed DC (♦). CTLs 
were measured using a flow cytometry based method against CaSki (closed symbol) and T2 (open symbol) target 
cells. The data were shown as mean ± SD (n = 3). 
 
4.3.5 DOTAP/E7 mediated proliferation and ERK activation in T cells 
As some of the recent developed adjuvants can directly act on T cells [28], we found that 
DOTAP/hE7 also interacts with human T lymphocytes, leading to clonal expansion and T cell 
activation. Enriched human lymphocytes obtained from an HLA-A2+ healthy donor were 
stimulated by DOTAP or DOTAP/hE7 which were directly added into the culture. The 
stimulation was repeated three times with a 7-day interval. Three days after the third stimulation, 
lymphocytes treated with DOTAP (Fig. 4.4b) or DOTA/E711-20 (Fig. 4.4d) showed extensive 
expansion of T cell colonies in culture in contrast to no clonal expansion in medium control (Fig. 
4.4a) and few colonies of expanding T cells in treating with E711-20 peptide alone (Fig. 4.4c). The 
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DOTAP-mediated T cell activation was further confirmed by ERK phosphorylation in T cells. 
As shown in Fig. 4.4e, human T cells treated with DOTAP at 50 μM induced a strong ERK 
phosphorylation with a maximum signal at 10 min after the treatment. The results suggested that 
DOTAP has a direct impact on T cell activation via a MAP kinase mediated cell proliferation. 
 
E 
 
Figure 4.4. DOTAP-induced human lymphocyte proliferation and activation.  
Human lymphocytes obtained from the HLA-A2 healthy donor were incubated with A, medium only; B, DOTAP 
(25 μM) alone; C, E711-20 (10 μM); D, DOTAP/E711-20 (containing 25 μM lipid and 10 μM peptide). Three days after 
the third stimulation, the images of the culture were taken by a phase contrast microscope. E, DOTAP-induced ERK 
phosphorylation was detected by Western blot analysis. 
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4.3.6 Antigen specificity of CTL response induced by DOTAP/E711-20 
Human T lymphocytes showed clonal expansion in response to both DOTAP and DOTAP/E711-
20 treatments (Fig. 4.4). These cells were tested for CTL response in killing of E711-20 pulsed T2 
(HLA-A2+, E7+) and OVA peptide pulsed T2 (HLA-A2+, E7-) target cells. As shown in Fig. 4.5a, 
DOTAP/E711-20 (■) stimulated T cells at high E:T ratio were capable of killing T2 targets which 
had been pulsed with E711-20 but not T2 pulsed with an irrelevant peptide (Fig. 4.5b). The 
specific killing capability was not observed when T cells were treated with medium, peptide 
alone nor DOTAP alone. The confirmation of antigen specificity of DOTAP/E711-20 induced 
CTL response was also provided by their ability to lyse CaSki cervical cancer cell line (data not 
shown). The experiment was repeated three times with different donor blood cells and the results 
were similar to each other. 
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Figure 4.5. Antigen specificity of the CTL response induced by DOTAP/hE7.  
CTL response was measured using a flow cytometry based method against E711-20 pulsed T2 (A) and OVA peptide 
pulsed T2 (B). Cytotoxicity was carried out at 1 week after the third stimulation of HLA-A2+ T lymphocytes with 
medium only (●); DOTAP alone (▼); E711-20 alone (▲); or DOTAP/E711-20 (■). The data were shown as mean ± SD 
(n = 3). One representative data from three performed was shown. 
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4.3.7 Augment of in vivo CTL responses in HLA-A2 transgenic mice after vaccination 
with DOTAP/hE7 formulations 
To access the in vivo immunogenicity of DOTAP/hE7, HLA-A*0201 transgenic mice were 
vaccinated with the DOTAP/E711-20 or DOTAP/E786-93 formulation and assayed for the in vivo 
CTL activity. A mixture of target cells containing E711-20 pulsed (CFSEhigh), E786-93 pulsed 
(CFSEmedium) and unpulsed (CFSElow) syngenic spleen cells was tail vein injected into the 
untreated, DOTAP/E711-20 vaccinated or DOTAP/E786-93 vaccinated A2 transgenic mice and 
allowed in vivo killing for 16 h prior to the FACS analysis. As shown in Fig. 4.6, the percentage 
of E711-20 specific killing in mice that were immunized with DOTAP/E711-20 formulation was 
more than 80%, while in the groups received DOTAP/E786-93 formulation showed about 35% of 
E786-93 specific killing. These results showed that DOTAP/hE7 formulation induced an HLA-A2 
restricted, antigen-specific CTL in vivo and the DOTAP/E711-20 formulation elicited a higher 
CTL activity than the DOTAP/E786-93 formulation. 
 
Figure 4.6. Peptide-specific CTL were induced in vivo in HLA-A2 Tg mice with DOTAP/hE7 immunization. 
Seven days after the second immunization, the representative mice from the untreated, DOTAP/E711-20 or 
DOTAP/E786-93 treated groups were iv injected with an equivalent amount of E711-20 pulsed (CFSEhigh), E786-93 
pulsed (CFSEmedium) and unpulsed (CFSElow) spleen cells from a syngenic donor. The in vivo CTL response was 
carried out for 16 h and the spleen cells from the recipient mice were analyzed by flow cytometry. 
 101 
4.3.8 Therapeutic effect of DOTAP/E711-20 against TC-1/A2 established tumor 
The therapeutic effect of DOTAP/E711-20 against the established TC-1/A2 tumor was confirmed 
in HLA-A*0201 transgenic mice (Fig. 4.7). TC-1/A2 was generated by transducing TC-1, an 
established E7-expressioing tumor cell line with a retrovirus encoding the HLA-A2 molecule 
[21]. TC-1/A2 tumor was established by subcutaneouly injecting 106 tumor cells into the A2 
transgenic mice on day 0. As shown in Fig. 4.7, mice treated with a single dose of DOTAP/E711-
20 on day 6 exhibited a significant reduction in tumor burden compared with the untreated mice 
(P = 0.002 on day 29). These data indicated that the DOTAP/E711-20 therapeutic vaccine was 
capable of inducing antigen-specific CTL activity responsible for an anti-tumor response in the 
presence of a growing tumor. 
 
 
Figure 4.7. Kinetics of TC-1/A2 tumor growth in HLA-A2 Tg mice with a single treatment of DOTAP/E711-20.  
A2 transgenic mice (n = 6) were subcutaneously injected with 106 TC-1/A2 tumor cells on day 0 and the mice were 
left untreated or treated with DOTAP/E711-20 on day 6. Tumor sizes were measured two or three times per week. 
Each line represents the tumor growth of an individual animal. Tumor size of the treated group on day 29 was 
compared to that of the untreated control and was analyzed statistically. 
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4.4 DISCUSSION 
Previous reports in our lab have shown the potency and the possible vaccine mechanism of 
DOTAP/E7 in a mouse model system, in which the murine H-2Db restricted E7 peptide (a.a. 49-
57) epitope was studied [18, 20]. The data presented in this report summarizes studies performed 
to extend our understanding of the DOTAP/E7 vaccine to human in vitro and in vivo systems by 
formulating HLA-A2 restricted CTL epitope (E711-20 or E786-93) into the DOTAP liposomes. In 
vitro testing in activation of human dendritic-like KG-1 cells and primary human DC (Fig. 4.1) 
indicated that DOTAP cationic lipids are potent immunostimulators, promoting dendritic cell 
activation toward expression of co-stimulatory molecules which were required for T-cell 
recognition and antigen presentation. We have also demonstrated that human DC, upon 
activation by DOTAP/hE7 liposomes, promoted significant proliferation of human T-cells in 
vitro (Fig. 4.2). In addition, human T-cells stimulated by DOTAP/hE7-activated autologous DC 
were capable of mounting a tumor-specific cytotoxic response in vitro (Fig. 4.3). Our data also 
showed the capability of DOTAP/hE7 to interact with human T cells, leading to clonal expansion 
and antigen-specific CTL response (Fig. 4.4 and Fig. 4.5). For in vivo demonstration, HLA-
A*0201 transgenic mice immunized by DOTAP/hE7 induced an in vivo antigen-specific 
cytotoxic T-cell response (Fig. 4.6). Finally, upon injecting a single dose of DOTAP/E711-20 to 
the TC-1/A2 (HLA-A2+, HPV E7+) tumor-bearing transgenic mice, suppression of tumor growth 
resulted as compared to the untreated animals (Fig. 4.7).  
The generation of mature human DC involves at least two stages [29]. The first stage 
includes the differentiation of CD34+ hemopoietic progenitors to the immature CD11c+/CD83+ 
DC lineage cells with the stimulation of fresh cytokines (e.g. GM-CSF and IL-4) replenished 
every 48-72 h [30] [31]. The immature DC is highly capable for antigen uptake but relatively 
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poor in activating T cells. The second stage of the process involves the activation of the 
immature, resting DC to the mature, fully stimulatory antigen-presenting cells (APC) by an 
addition of a danger signal, such as TNF-α and LPS. Along this process, DC loses antigen-
capturing ability but is much more potent in activating T cells [32]. The data shown in Fig. 4.1 
indicated that DOTAP was sufficient to trigger DC activation compared to the potent stimuli of 
phobol ester PMA, which activates protein kinase C, plus a calcium ionophore ionomycin [33]. 
Upon DOTAP stimulation, the danger signal which is required for DC maturation was likely 
provided by the production of the reactive oxygen species (ROS) in DC [18]. In addition, the 
subsequent signals mediated by DOTAP stimulation, such as CCL2 chemokines and ERK 
activation also contributed to promoting survival of DC [20] [34]. 
Naïve CD8+ T cells require interaction with antigen-presenting cells to achieve full 
activation of cell-mediated immune responses [35]. Presentation by mature DC results in 
antigen-specific CTL, however, antigen presented by inactivated DC to T cells induces tolerance 
[36] [37]. To avoid tolerance, during the process of in vitro DC-naïve T cell incubation, it is 
critical to have antigen-presenting DC fully activated prior to encounter with T cells. Our data 
shown in Fig. 4.2 and Fig. 4.3 also supported the notion that DC being activated by DOTAP/hE7 
elicited a stronger clonal T cell proliferation and higher HPV-specific CTL responses as 
compared to those pulsed only with E7 peptide. 
It has been extensively studied that several adjuvants of bacterial origins are designed to 
comprise pathogen-associated molecular patterns (PAMP) which are recognized by toll like 
receptors (TLR) on DC or macrophages [38]. The well-tolerant and effective adjuvants, 
monophosphoryl lipid A (MPL) and its chemical mimetic RC529 have been shown to signal 
through TLR4 [39] [40]. MPL activates human monocyte-derived DC at high dose of 100 μg/ml. 
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Similar to its parental molecule LPS, MPL also acts on T cells directly [28]. Our data showed 
that DOTAP cationic lipid activated human DC at 50 μM (~35 μg/ml) and it also induced 
ERK1/2 phosphorylation in T cells, leading to T cell proliferation (Fig. 4.4). Unlike MPL and 
LPS which induce a strong NF-κB production through TLR signaling, DOTAP does not induce 
NF-κB activity nor TNF-α production [41] [19]. Our result is opposite to the traditional adjuvant 
concept that the more inflammatory the adjuvant is, the better immunostimulatory responses. 
Unlike some soluble adjuvants, DOTAP delivers the antigen (e.g. E7) into APC (e.g. DC) 
via a particulate manner, while it stimulates DC activation/maturation at the same time. The 
mechanism of the interaction between DOTAP/E7 and DC is fairly similar to that of 
multivesicles or exosomes which are produced by APC [42] [43]. Indeed, exsomes are 
membrane-bound molecules with the size less or equal to 100 nm. Similar to our previous results 
demonstrating that DOTAP/E7 complex is mainly taken up by DC in vivo [18]; exosomes also 
are internalized and processed by immature DC [44]. Recent studies show that exosomes 
exchange peptide-MHC complexes between DC, and the eradication of established tumor is 
observed following a treatment of DC-derived exosomes [45] [46].  
Results presented in Fig. 4.4 showed that both DOTAP and DOTAP/E711-20 induced 
extensive colonies of expanding T cells. However, only T cells stimulated with DOTAP/E711-20 
exhibited the antigen specific CTL capability (Fig. 4.5). This unusual observation suggests that 
DOTAP not only interacts directly with T cells, it delivers the antigen to T cells while activates 
them at the same time. The detail mechanism how DOTAP introduces antigen to T cells is 
unknown. Since the activated T cells express co-stimulatory molecules (CD80 and CD86) on the 
surface, the antigen presentation may occur through the interaction between two T cells. We also 
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cannot rule out that the DOTAP-activated B cells existing in the culture may also play a role in 
the antigen presentation to T cell. 
Both of the HLA-A2 restricted peptides, E711-20 and E786-93 which were predicted by Kast 
et al. [47] elicited immunogenicity when formulated in our liposomal vaccine formulation. The 
activity of the in vitro induced E711-20 CTL, however, appeared to be superior to that of E786-93 
CTL in killing CaSki cervical cancer cells (Fig. 4.3). A supportive result can be seen in the 
HLA-A2 transgenic mouse model (Fig. 4.6) that in vivo CTL response generated by 
DOTAP/E711-20 formulation was stronger than that induced by DOTAP/E786-93 in eliminating 
peptide-pulsed targets. Some of the previous reports showed that A2 transgenic mice vaccinated 
with E7 protein or E7-producing DNA vaccine did not generate E786-93 specific CTL responses 
[21] [48]. Although the reduced immunogenicity of E786-93 observed in this report may be due to 
the lower peptide entrapment efficiency in the liposome (Table 4.1), there is also a possibility 
that human cervical tumor cells may not always naturally present this epitope [14] [49].  
The clinical application of DOTAP/E7 vaccine in human is substantially broader than our 
previous vaccine version, LPD/E7, which consists not only lipid and peptide antigen but also 
CpG-containing plasmid DNA and polycations for DNA condensation [50]. Despite the possible 
side effects caused by the bacterial CpG motifs, it is also costly to manufacture clinical grade 
DNA. The in vivo cell-mediated immune responses elicited by subcutaneously injection of 
DOTAP/hE7 to the HLA-A2 transgenic mice (Fig. 4.6 and Fig. 4.7) indicated the in vivo 
efficacy and potentials of DOTAP/hE7 vaccine being administered directly to the patients. 
We also observed that the anti-tumor effect of DOTAP/E711-20 to the TC-1/A2 tumor (Fig. 
4.7) was not as strong as that of DOTAP/E749-57 to the murine TC-1 tumor model [18], likely 
owing to the insufficient expression of HLA-A2 molecules on the surface of TC-1/A2 cell (data 
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not shown). The observation was in accordance to other previous studies using TC-1/A2 or 
HLF16, a similar HLA-A2+ HPV E7+ tumor cell line [51] [52]. 
In summary, the data in this report demonstrated that the DOTAP/hE7 vaccine induced 
cell-mediated anti-tumor immune response as seen in murine model studies can be applied in 
human in vitro and in a transgenic murine model. Further testing of DOTAP/hE7 vaccine on 
PBMC obtained from cervical cancer patients would greatly improve the understanding of the 
dosing and the efficacy of the vaccine prior to the clinical application. 
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5.0  DISCUSSION 
5.1 CONCLUSION AND FUTURE DIRECTIONS 
The evidences provided in this report demonstrate a great potential of DOTAP/E7 therapeutic 
vaccine for future clinical trials. The value of this work lies in the simplification of the vaccine 
design and the clarification of the immune responses induced by this simple vaccine. Our 
unpublished data show that mice were 100% protected by DOTAP/E7 immunization from the 
TC-1 tumor challenge, indicating DOTAP/E7 vaccine is also effective as a preventative vaccine 
against HPV+ nascent tumor.  
 
The data presented in Chapter 4 suggest at least three feasible clinical applications of the 
DOTAP/hE7 vaccine. First approach is to inject vaccines directly into the patients. We have 
demonstrated in an HLA-A2 transgenic mouse model that immunization with DOTAP/hE7 
generates antigen-specific CTL response which translates to the anti-tumor activity in the tumor 
(HLA-A2+, HPV+) bearing mice. Secondly, an improved DC vaccine can be achieved by ex vivo 
stimulating autologous DC with DOTAP/hE7 formulation. In addition to the delivery of the 
antigen to DC, our data show that DOTAP also activates human DC toward the expression of 
CD80, CD86 and CD83 markers, which agrees with the previous observation obtained from a 
mouse model. Furthermore, the naïve human T cells can be stimulated by DOTAP/hE7 activated 
DC, resulting in clonal expansion and exhibited antigen specific CTL activity. Since maturation 
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of antigen-primed DC results in an enhanced antigen presentation capability as well as 
immunogenicity compared to the immature DC [1], several recent strategies in developing 
cancer immunotherapy involve the use of mature DC [2]. The most characterized DC-maturing 
agents are inflammatory cytokines such as corss-linking of TNF superfamily [3]. Unlike these 
inflammatory agents, DOTAP does not induce NF-κB in DC, indicating a unique pathway of DC 
activation. Thus, DC activated by DOTAP/hE7 could be safely used for autologous adoptive 
transfer therapy. 
 
Finally, the third clinical approach may be carried out using ex vivo preparation of human 
T cells directly activated by DOTAP/hE7. Our data provide the evidence that DOTAP interacts 
with human T cells, leading to the ERK phosphorylation in the T cells. Upon the treatment of 
DOTAP or DOTAP/hE7, the expanding T cell colonies were observed in the culture. However, 
only the cells treated with DOTAP/hE7 exhibited CTL capability with antigen specificity. Based 
on these results, a model is proposed in Fig. 5.1. The upper panel of the illustration shows 
antigen presentation by DC which is believed as a central dogma. DOTAP/E7 is taken up by DC 
via endocytosis. T cells are activated by mature DC through the interaction of peptide-MHC-
TCR complex and costimulatory signals. The lower panel of the illustration proposes a possible 
antigen presentation process in the absence of DC. The detail mechanism how DOTAP delivers 
the antigen to T cells is unclear. Since T cells are not known as professional antigen presenting 
cells, it is questionable that T cells would present antigen the same way as APC (i.e. DC). The 
activated T cells express costimulatory molecules (CD80 and CD86) such that the event of 
antigen presentation may occur between two T cells followed by subsequent immune responses. 
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 Figure 5.1. A proposed model for antigen presentation and immune responses mediated by DOTAP/hE7 
therapeutic vaccine. 
 
Despite many superior advantages of the DOTAP/E7 vaccine formulations described in 
the previous chapters, there are some issues that deserved more discussion. In Fig. 2.4, the high 
dose of DOTAP seems to be capable of stimulating CTL using a traditional CTL assay method 
which requires in vitro stimulation of responder T cells for 5 days in the presence of peptide. We 
cannot rule out the possibility that the true functionality of CD8+ cells was overestimated after in 
vitro expansion of the subset cells. On the contrary, an in vivo CTL result (Fig. 2.5A) gave us a 
more trustworthy estimation of the functionality of CD8+ T cells elicited in the mice. Our in vivo 
CTL results indicated that high dose of DOTAP does not generate efficient CTL in vivo. 
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Although DOTAP at high dose could generate a good NK response toward a non-specific killing, 
the effect contributed little to the anti-tumor activity. It is not clear at present the role of NK cells 
play in the overall anti-tumor activity induced by DOTAP/E7. Also, the in vivo CTL result 
shows that DOTAP/E7 vaccine was able to induce antigen-specific CTLs in the spleen, 
indicating E7-specific T cells present in DLN have migrated to the secondary lymphoid organ. It 
is believed that patrolling cells of the immune system provide continuously body-wide 
surveillance, spying out and eliminating tumor cells. However, we do not have information on 
the antigen-specificity of T cells at the tumor sites.  
 
Our data in Chapter 2 have indicated that the reduced anti-tumor activity of DOTAP/E7 
at high dose lipid was associated with higher level of Tregs, probably owing to the excess ROS 
production and cell death in DC. Although the excess amount of ROS signal induces DC 
apoptosis, however, it is now known that ROS at low concentrations serve as an essential second 
messenger mediating cellular responses to many physiological stimuli [4]. DC treated with 
antioxidants are resistant to phenotypic and functional changes following stimulation with 
proinflammatory cytokines [5]. Following treatment with antioxidants, the levels of intracellular 
ROS are reduced, and the protein kinase RNA-regulated NF-κB, protein kinase C, and p38 
MAPK pathways could not be activated following inflammatory agent stimulation [5]. Also ROS 
are shown in the DC interaction with T cells. For example, both T cells and DC elevate 
intracellular oxidation states upon Ag-specific interaction. Ebselen, an antioxidant, at 5–20 µM 
concentrations inhibits DC-induced proliferation and cytokine production by T cells as well as T 
cell-induced cytokine production by DC [6]. ROS also induce early phenotypic maturation of DC 
by up-regulating specific markers CD80, CD83, and CD86 and down-regulating mannose 
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receptor-mediated endocytosis [7]. Recently, cationic liposomes were reported to generate the 
ROS in macrophages leading to activation of the p38 pathway [8]. Therefore, cationic DOTAP 
liposome-induced ROS in antigen presenting cells plays a positive and essential role in the 
generation of immune response to protect the host. 
 
Although immunization with the hE7 peptide (CTL epitope) resulted in a potent anti-E7 
and tumor specific activity, immunization with the whole E7 protein might be more effective 
because there are multiple MHC class I and II restricted epitopes on the protein. The existence of 
highly diverse MHC I and II molecules among human populations also makes the whole E7 
protein more attractive [9]. Instead of using the E7 peptide which encodes a single CTL epitope, 
the entire E7 protein formulated into cationic DOTAP liposome is an alternative strategy. The 
production of antibody response and the proliferation of CD4+ T lymphocytes are the additional 
benefits of the protein antigen.  
 
An interesting finding from an unpublished in vitro result using fluorescent NBD-
DOTAP treated mouse spleen cells shows that CD40+ B-cell population  tends to uptake (bind to) 
a higher amount of DOTAP compared to other cell types (Fig. 5.2). The profile of NBD-DOTAP 
uptake by total spleen cells is shown in grey color (upper left). Despite the fact that NBD were 
taken up by both CD3+ T (lower left, blue) and CD40+ B cells (upper right, yellow), the intensity 
of NBD signal in B cells was 3-fold and 7-fold stronger than that in CD4+ (green) and CD8+ (red, 
lower right) T cells, respectively. This result implies that B cells may have more surface 
molecules that recognize/interact with DOTAP compared to other spleen cells. 
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 Figure 5.2. In vitro NBD-DOTAP uptake by mouse spleen cells. 
Single cell suspension of mouse spleen cells were prepared and 50 μM DOTAP containing 1% fluorescent NBD-
DOTAP was added into the culture. Spleen cells were harvested and label with cell surface marker prior to analysis 
by flow cytometry. 
 
 
Furthermore, a separate experiment shown in Fig. 5.3 that DOTAP can activate B cells, 
leading to expression of CD86 expression. The amounts of CD19+/CD40+ (blue dots) and 
CD19+/CD40- (yellow dots) B cells were significantly increased after DOTAP stimulation in 
vitro. Cells gated within upper-right and lower-right quadrants were further analyzed for the 
expression of CD86 (shown in histogram). The data show that DOTAP induced the expression of 
CD19+ molecule (a BCR co-receptor) as well as an activation marker (CD86) on B cells. Based 
on these preliminary data, we conclude DOTAP is efficient on activating B cells, thereby a B-
cell targeted delivery by DOTAP can be proposed. 
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 Figure 5.3. B cells are activated by DOTAP stimulation in vitro.  
The dot plot and histogram on the left show the phenotype of untreated cells compared to that of the DOTAP treated 
cell on the right. The numbers shown on the dot plot represent the percentage of cell number for each quadrant. 
 
 
The future directions of DOTAP/E7 vaccine project include the study of the interaction 
between DOTAP and other immune cells such as T and B cells. We have previously focused on 
the DOTAP-mediated signaling pathways in DC; however, results presented in this report show 
DOTAP also interact directly with other types of cell which deserved further investigation. We 
are also interested in discovering new cationic lipids which may exhibit an enhanced immune-
modulatory effect compared to DOTAP. 
 
It is also tempting to combine DOTAP/E7 vaccine with other active therapeutic strategies. 
Immunotherapy has been developed as an adjuvant therapy for human cancer for many years 
with limited success [10] [11]. One of the major reasons for failure is the fact that cancer patients 
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are frequently immuno-compromised, either due to the cancer growth itself or, more significantly, 
the use of various chemotherapeutic agents or radiation. Thus, it is important that any treatment 
prior to the immunotherapy does not suppress the immune system.  Since one can use siRNA to 
silence specific target genes such that tumor apoptosis can be induced in the primary tumor 
without immune compromise, the subsequent immunotherapy should be more effective than if it 
is preceded by chemotherapy. Our lab has proposed an ideal method to induce primary tumor 
apoptosis and introduce cytokine at the same time via i.v. injection. It requires a specific tumor 
delivery of both plasmid DNA and apoptotic inducing agents without suppressing the immune 
system of the host (unpublished data).  
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